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1 Abstract 
1. Abstract 
 
Dimethyl fumarate (DMF) is approved for treatment of relapsing remitting multiple sclerosis 
(RRMS), a chronic inflammatory disease of the central nervous system (CNS) that is caused by 
autoreactive T cells. The effect mechanism of DMF is not fully elucidated so far; however, a 
preferential impact on CD8+ T cells was described. In the cerebrospinal fluid (CSF) of MS 
patients IL-17-producing CD8+ T (Tc17) cells are enriched. In addition, during experimental 
autoimmune encephalomyelitis (EAE), the mouse model for multiple sclerosis (MS), a co-
pathogenic function of Tc17 was described. Hence, Tc17 cells crucially contribute to 
autoimmune processes in the CNS of men and mice.  
This study shows that DMF elevated reactive oxygen species (ROS) in CD4+ T (Th17) cells and 
Tc17 cells by glutathione depletion, resulting in IL-17 suppression particularly in Tc17 cells. 
Accordingly, IL-17 production by CD8+ but not by CD4+ T cells was reduced in DMF-treated MS 
patients and DMF application diminished Tc17 cell pathogenicity in EAE. Accumulated ROS 
shifts the Tc17 transcriptome towards a cytotoxic T lymphocyte (CTL)-like signature by 
enhancing IL-2 signalling including phosphoinositide-3-kinase (PI3K)/ protein kinase B (AKT) 
and signal transducer and activator of transcription (STAT)5 pathways. AKT deactivated 
forkhead-box-Protein O (FOXO)1 leading to the upregulation of the transcription factor T-box 
transcription factor TBX21 (T-bet), which in turn suppressed IL-17. The modified transcriptional 
network was accompanied by altered histone modifications at the Il17 locus. In line, T-bet-
deficiency, inhibition of histone deacetylases (HDAC), PI3K/AKT or STAT5 partially prevented 
DMF-mediated suppression of Tc17 cells. 
Thus, this work provides mechanistic insights into the selective modulation of Tc17 cell 
differentiation by DMF-mediated upregulation of ROS and IL-2 signalling with relevance for 
Tc17-driven pathologies including MS and psoriasis.  
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1. Zusammenfassung 
 
Dimethylfumarat (DMF) wird zur Behandlung von schubförmig remittierender multipler 
Sklerose (RRMS) eingesetzt, einer chronisch-entzündlichen Erkrankung des zentralen 
Nervensystems (ZNS), die von autoreaktiven T-Zellen verursacht wird. Der Wirkmechanismus 
von DMF ist nicht vollständig aufgeklärt; es ist jedoch bekannt, dass insbesondere CD8+ T-
Zellen beeinflusst werden. IL-17-produzierende CD8+ T-Zellen (Tc17) sind in der 
Zerebrospinalflüssigkeit (CSF) von MS-Patienten angereichert. Zusätzlich wurde die ko-
pathogene Wirkung von Tc17-Zellen in der experimentellen autoimmunen Enzephalomyelitis 
(EAE), dem Mausmodell für MS, beschrieben. Diese Beobachtungen legen nahe, dass Tc17-
Zellen zu autoimmunen Prozessen im ZNS bei Mensch und Maus beitragen. 
Die vorliegende Studie zeigt, dass DMF durch Glutathiondepletion in IL-17-produzierenden 
CD4+ T-Zellen (Th17) und Tc17-Zellen Sauerstoffradikale anreicherte und dies besonders in 
Tc17-Zellen zu einer IL-17 Suppression führte. Dementsprechend konnte eine reduzierte IL-17-
Produktion in CD8+ T-Zellen, nicht jedoch in CD4+ T-Zellen von DMF-behandelten MS-Patienten 
nachgewiesen werden. Ebenso verminderte die Verabreichung von DMF die Pathogenität von 
Tc17-Zellen in der EAE. Die Akkumulation von Sauerstoffradikalen trieb das Transkriptom von 
Tc17-Zellen in Richtung einer cytotoxischen T-Zell Signatur. Mechanistisch wurde dies durch 
die Verstärkung von IL-2-Signalwegen, wie Phosphoinositid 3-Kinase (PI3K)/ Proteinkinase B 
(AKT) und STAT5 realisiert. AKT deaktivierte FOXO1, einen Suppressor des 
Transkriptionsfaktors T-bet. Die daraus resultierende Induzierung von T-bet führte letztendlich 
zu einer IL-17 Hemmung. Die Modifizierung des transkriptionellen Netzwerks ging mit 
veränderten Histonmodifikationen am Il17 Locus einher. Übereinstimmend konnten sowohl T-
bet-Defizienz als auch die Inhibierung von Histon-Deacetylasen (HDAC), PI3K/AKT oder STAT5 
die DMF-vermittelte Tc17-Suppression teilweise verhindern. 
Zusammenfassend liefert diese Arbeit mechanistische Einblicke in die selektive Modulation der 
Tc17-Zelldifferenzierung durch eine DMF-vermittelte Induzierung von Sauerstoffradikalen und 
IL-2 Signalwegen und ist daher relevant für Tc17-vermittelte Krankheitsbilder wie MS und 
Psorias. 
 
  
3 Introduction 
2. Introduction  
 
2.1 Pivotal role of T cells during immune responses 
The immune system is a complex network consisting of various cellular and soluble 
components that cooperate in order to protect the human body against pathogens and the 
development of cancer. However, misguided immune responses can evoke allergy or 
autoimmunity that represent important pathologies in industrialised nations.  
Immune cells are derived from pluripotent hematopoietic stem cells and are categorised into 
the myeloid lineage, including dendritic cells (DC), macrophages, granulocytes, mast cells and 
erythrocytes or to the lymphoid lineage such as NK cells, innate lymphoid cells (ILC), T and B 
cells. T lymphocytes are further classified into cluster of differentiation (CD)4+ T helper (Th) 
and CD8+ cytotoxic T (Tc) cells, which differ in their reactivity to the major histocompatibility 
complex (MHC). Whereas the T cell receptor (TCR) of CD4+ Th cells binds peptide-loaded MHC 
class II molecules located on professional antigen-presenting cells (APC), all nucleated cells 
contain MHC class I that is recognised by the TCR of CD8+ T cells. During thymic selection, 
TCR/MHC interaction ensures that only T cells survive which bind to MHC molecules (positive 
selection) without reacting to self-antigens (negative selection). The naïve T cells that remain 
after this selection are largely non-responsive to self but capable of responding to foreign 
peptides and egress into the blood and lymphatic circulation. The activation of naïve T cells 
into effector T cells by APCs in lymphoid organs is realised by the interaction of TCR/MHC 
together with costimulatory stimuli and cytokine signalling, however recent data also imply the 
contribution of reactive oxygen species (ROS) in this process (Franchina, Dostert, & Brenner, 
2018). At the end of a primary immune response, the majority of responding T cells dies by 
apoptosis. However, a small percentage survives and gives rise to immunological memory, a 
characteristic of the adaptive immunity. It is acquired by the development of memory T cells 
that ensure a fast and effective immune response in case of re-exposure to the cognate 
antigen (Murphy & Weaver, 2017). Human memory cells are further specified into central 
memory (TCM), effector memory (TEM) and effector memory T cells (TEMRA), depending on 
the expression of CC-chemokine receptor (CCR)7 and CD45RA (Geginat, Lanzavecchia, & 
Sallusto, 2003). 
During immune responses, CD4+ and CD8+ T cells have distinct roles: Th cells coordinate 
specific immune responses by their cytokine production, whereas CD8+ T cells are able to kill 
target cells directly by inducing apoptosis through cytotoxic molecules like perforins or 
granzymes, in addition to cytokine production. However, in order to guarantee an efficient 
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immune response tailored to tumour cells and the variety of pathogens, the generation of 
distinct subsets of CD4+ and CD8+ T cells is required. The differentiation into subpopulations 
with specific defence mechanisms is driven by the surrounding cytokine milieu during T cell 
activation (Murphy & Weaver, 2017). The subsets differ particularly in their specific 
transcription factors (TF), cytokine profiles as well as their characteristic effector functions. In 
1986, Mosman et al. first described the existence of interferon (IFN-)-producing Th1 and IL-4-
producing Th2 cells (Mosmann, Cherwinski, Bond, Giedlin, & Coffman, 1986) since then a great 
number of CD4+ T cell subsets has been discovered, demonstrating the complexity of 
immunological responses. Beside Th1 and Th2 cells, IL-9-producing Th9 cells, regulatory T 
(Treg) cells, follicular T helper cells and Th17 cells with their signature cytokine IL-17 are known 
and orchestrate immune responses against specific pathogens (J Zhu, Yamane, & Paul, 2010). 
Recent data show that also CD8+ T cells can be subdivided into different subtypes, comparable 
to their CD4+ counterparts. Besides classical cytotoxic T lymphocytes (CTL or Tc1) also Tc2, Tc9, 
CD8+ Treg and Tc17 cells have been described (Mittrücker, Visekruna, & Huber, 2014). 
 
2.2 T cells in health and disease 
Both, CD4+ and CD8+ T cells play central roles in the function of the immune system by clearing 
diverse pathogens and eliminating of tumorigenic cells. However, due to their central function 
in immune responses, dysregulation of T cells can have tremendous consequences and lead to 
pathological immune reactions as allergy or autoimmunity (J Zhu et al., 2010). Therefore, the 
variety of T cell subsets and their functional diversity have the potential to initiate a multitude 
of pathologies.  
 
2.2.1 Protective and pathogenic functions of CD4+ T cells 
On the one hand, Th1 cells contribute to the clearance of intracellular pathogens by activating 
macrophages via their IFN- production (Jinfang Zhu & Paul, 2008) but on the other they can 
also contribute to delayed-type hypersensitivity responses and autoimmunity (Damsker, 
Hansen, & Caspi, 2010). Combating extracellular pathogens, such as worms, is mediated by  
IL-4, IL-5 and IL-13-producing Th2 cells and subsequent activation of B cells, however 
dysregulation can induce allergic responses (Damsker et al., 2010). Similar to Th2, also Th9 
cells combat against parasites and in addition possess anti-tumour immunity by producing IL-9. 
On the other side, they can also contribute to the induction of allergy and asthma (Carrascosa 
et al., 2017; Kaplan, Hufford, & Olson, 2015; J Zhu et al., 2010). The clearance of intracellular 
pathogens is mediated by Th17 cells, which produce pro-inflammatory IL-17, IL-21 and IL-22 
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and thereby trigger neutrophil recruitment to the infection side (Jinfang Zhu & Paul, 2008). 
However, the ability to induce inflammation predetermines Th17 cells to contribute to the 
development of autoimmune disorders such as multiple sclerosis (MS), rheumatoid arthritis, 
Crohn’s disease and many others (Tabarkiewicz, Pogoda, Karczmarczyk, Pozarowski, & 
Giannopoulos, 2015). In order to prevent autoimmunity and maintain immune homeostasis, 
Treg cells secrete anti-inflammatory cytokines as TGF- and IL-10 (Jinfang Zhu & Paul, 2008), 
but the suppression of immune responses makes them to key-players in tumour progression 
(Chaudhary & Elkord, 2016), impressively demonstrating the requirement of fine-tuned 
immune responses.  
 
2.2.2 Protective and pathogenic functions of CD8+ T cells 
CD8+ T cells fulfil crucial functions in immune responses against intracellular pathogens and 
tumours  (Klenerman & Hill, 2005; Y. Lu et al., 2014; Su, Lee, & Kung, 2010; Sukumar et al., 
2013), but also contribute to allergic and autoimmune disorders (Huber et al., 2009; Loser et 
al., 2010; Tang et al., 2012; Visekruna et al., 2013). The best-characterized subset of CD8+ T 
cells are CTLs, which can kill infected or cancerous cells directly by releasing cytotoxic 
molecules and production of cytokines as IFN- and tumour necrosis factor (TNF)- (Kaech & 
Cui, 2012), but they are also implicated in autoimmune processes (Blanco, Viallard, Pellegrin, & 
Moreau, 2005). Similar to Th2 cells, Tc2 cells secrete IL-4, IL-5 as well as IL-13 and can show 
high or low cytotoxicity, dependent on the type of immune response (Mittrücker et al., 2014). 
Functionally, they contribute to rheumatoid arthritis (Cho et al., 2012) and Th2-mediated 
allergy (Tang et al., 2012). Th2/Tc2-dependent airway inflammation is further promoted by IL-
9- and IL-10-producing Tc9 cells (Visekruna et al., 2013), however, this subset is also implicated 
in the provision of a strong anti-tumour response via IL-9 (Y. Lu et al., 2014). CD8+ Tregs reflect 
to large extend the properties of CD4+ Treg by secreting anti-inflammatory IL-10 and TGF-, 
determining them to important regulators of T cell-mediated responses (Mittrücker et al., 
2014). However, comparable to their CD4+ counterparts, also CD8+ Treg cells at least partially 
promote tumour progression (Zhang et al., 2015) and contribute to autoimmune diseases such 
as lupus (Dinesh, Skaggs, La Cava, Hahn, & Singh, 2010).  
Similar to Th17 cells, also murine Tc17 cells produce the pro-inflammatory marker cytokine  
IL-17A and can co-secrete further cytokines including IL-17F, IFN- granulocyte monocyte-
colony stimulating factor (GM-CSF), IL-21, IL-22 or TNF- (Srenathan, Steel, & Taams, 2016). A 
high plasticity towards IFN- production as well as variability in cytotoxicity have been 
reported and represent characteristic features of Tc17 cells (Srenathan et al., 2016). Due to the 
production of pro-inflammatory IL-17, they provide immunity against bacterial, viral and fungal 
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infections (Hamada et al., 2009; Naik et al., 2015; Nanjappa et al., 2017; Yeh et al., 2010) on 
the one hand, but there is strong evidence for a pathogenic function of Tc17 cells in 
autoimmunity on the other. Amongst others, their contribution to MS (Huber et al., 2013), 
psoriasis (Kryczek et al., 2008) and autoimmune colitis (Tajima et al., 2008) has been reported. 
The function of Tc17 cells in anti-tumour responses is contradictory and ranges from clearance 
of cancer to promoting of tumour growth (Hinrichs et al., 2009; Kuang et al., 2010). 
It was demonstrated that CD8+ T cell subtypes can acquire the characteristic cytokine 
production of other subpopulations, while retaining the initial cytokine production, a 
phenomenon called T cell plasticity (Zhou, Chong, & Littman, 2009). Thus, Tc17 cells positive 
for IL-17 and IFN- or Tc2 cells that co-express IFN- together with IL-4 and IL-10 were detected 
(Mittrücker et al., 2014). 
 
Figure 1: Plasticity of CD8+ T cell subsets and their specific cytokine production 
Similar to CD4+ T cells, CD8+ T cells also show lineage plasticity and acquire different subset phenotypes 
described as CTL, Tc2, Tc9, Tc17 and CD8+ Treg. These subsets produce specific cytokines and cytotoxic 
molecules to combat pathogens and tumour development. Arrows show the ability of cells to acquire 
characteristics of the other Tc subsets. Modified from (Mittrücker et al., 2014). 
 
2.3 Multiple sclerosis 
Worldwide, approximately 2.5 million people suffer from MS, a disease of the central nervous 
system (CNS) that mainly affects young adults between 20 and 40 years of age, especially 
women. During the course of the disease, autoreactive immune responses cause the 
development of lesions in the CNS, leading to disturbed neuronal signalling. Dependent on the 
location of lesions, clinical manifestation is heterogenous and can include motor impairments 
up to fatigue or visual disturbances (Dendrou, Fugger, & Friese, 2015). Intense research over 
the past years led to a better understanding of the mechanisms involved in MS pathogenesis 
and the development of new therapeutics however, until now there is no effective cure for the 
disease (Comabella & Khoury, 2012).  
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2.3.1 Pathogenesis of multiple sclerosis 
MS is an inflammatory disease of the CNS, which is considered to be caused by autoreactive T 
cells that initiate immune responses against myelin antigens such as myelin basic protein 
(MBP) or oligodendrocyte glycoprotein (MOG) (Dendrou et al., 2015; Nylander & Hafler, 2012). 
Usually, autoreactive T cells are killed during the selection process in the thymus; however, 
this process is imperfect, leading to the release of some autoreactive T cells in the periphery. 
During functional immune regulation, these cells are controlled by peripheral tolerance 
mechanisms. If this tolerance is dysregulated, autoreactive CD4+ and CD8+ T cells can be 
activated by self-antigen presenting cells and infiltrate the CNS, leading to inflammation and 
tissue damage by re-activation and specific effector functions (Dendrou et al., 2015). Both, 
genetic and environmental factors, including infectious agents, can contribute to this process 
and thereby lead to manifestation and progression of the disease (Dendrou et al., 2015). The 
development of inflammatory lesions is a hallmark of MS pathology and caused by immune 
cell infiltration across the blood-brain barrier (BBB) that initiates inflammation. This process 
leads to focal demyelination, neuroaxonal injury and in the end loss of neurological function 
(Dendrou et al., 2015). 
In order to understand the pathogenesis of MS, the animal model experimental autoimmune 
encephalomyelitis (EAE) was established 70 years ago (Rivers, 1933). EAE is induced by 
immunisation of mice with myelin peptides or by transfer of myelin-reactive T cells (Holmøy & 
Hestvik, 2008). Despite the fact that EAE provided important pathogenic mechanisms for the 
development of MS therapies, one has to keep in mind that this model cannot cover the entire 
spectrum of the immunological and pathological features of the disease (’t Hart, Gran, & 
Weissert, 2011; Lassmann, 2017). 
The pathology of MS is subdivided into four major types, based on the course of disease. The 
most common form is the relapsing-remitting MS (RRMS), affecting 80-90% of MS patients 
(Goldenberg, 2012). This type is characterised by relapses followed by remission phases, when 
symptoms improve or disappear. Over time this course often converts into the secondary 
progressive MS with or without periods of remission and progressive neurological deficits. The 
primary progressive MS affects 10 % of the patients and is marked by symptoms worsened 
from the beginning without relapses or remission. The forth type, progressive-relapsing MS, is 
a rare form with progressive course from the start and intermittent flare-ups, without periods 
of remission (Goldenberg, 2012; Loma, 2011).  
The aforementioned MS types are used to predict the course of the disease, but besides 
prognosis purpose they are also important for treatment decisions. Nowadays many drugs 
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against MS exist that reduce relapses; however, they cannot substantially cure the disease or 
reverse axonal damage (Dendrou et al., 2015).  
 
 
Figure 2: Typical course of the four major MS types 
(A) Relapsing-remitting MS (RRMS) is the most common type that is characterised by times of relapses 
and recovery. (B) Secondary-progressive MS (SPMS) is marked by initial relapses, followed by gradual 
increase of disability that is not associated with acute attacks. (C) Primary-progressive (PPMS) patients 
show a steady functional decline from the onset of disease without relapses or remission phases. (D) 
Progressive-relapsing MS (PRMS) is characterised by steady functional decline from onset of disease 
with acute relapses. 
 
B cells have been shown to contribute to the pathogenesis of MS by mediating aberrant T cell 
activation in the periphery and by producing myelin-specific auto-antibodies that are found in 
the serum and cerebrospinal fluid (CSF) of some patients (Pröbstel, Sanderson, & Derfuss, 
2015). The treatment with B cell-depleting anti-CD20 monoclonal antibodies (mAb) 
ameliorated the disease, underlining the important role of B cells in MS pathogenesis (Hauser 
et al., 2008; Michel et al., 2015). In addition, some studies suggest the involvement of innate 
immune cells such as macrophages, microglial cells and DCs to the pathogenesis of MS by 
influencing the effector functions of B and T cells (Gandhi, Laroni, & Weiner, 2010; Mishra & 
Yong, 2016).  
For a long time, autoreactive IFN--producing Th1 cells were considered to be the key-
mediators of MS pathogenesis (Compston & Coles, 2008). Further studies demonstrated the 
contribution of various cell types and T cell subsets, with a central role of Th17 cells 
(McFarland & Martin, 2007). In addition, it was shown that MS patients show reduced Treg 
function, although similar numbers in MS patients and controls have been found (Haas et al., 
2005). Besides the involvement of CD4+ T cells, growing evidence supports the pathogenic role 
of CD8+ T cells in the pathogenesis of MS (Denic, Wootla, & Rodriguez, 2013). It was found that 
CD8+ T cells even outnumber the numbers of CD4+ T cells in CNS parenchyma and active lesions 
of MS patients (Babbe et al., 2000; Booss, Esiri, Tourtellotte, & Mason, 1983), suggesting a 
critical contribution to the disease. As IL-17-producing T cells contribute to the pathogenicity 
of MS, they will be discussed in more detail in the following chapter. 
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2.3.2 Contribution of Tc17 and Th17 cells to MS pathogenesis 
A number of studies highlight the important role of IL-17-producing CD4+ and CD8+ T cells in 
the development and pathogenesis of MS and EAE (Huber et al., 2013; Komiyama et al., 2006; 
Tzartos et al., 2008). Both, Th17 and Tc17 cells have been detected in acute and chronic MS 
lesions (Tzartos et al., 2008). In RRMS patients, high frequencies of Th17 cells are found in the 
CSF during relapses, whereas patients in remission show lower numbers (Brucklacher-Waldert, 
Stuerner, Kolster, Wolthausen, & Tolosa, 2009). In addition, MS severity was shown to 
correlate with a high expression of IL-17 (Matusevicius et al., 1999), further suggesting key 
functions in the pathogenesis. 
Previously it was thought that Th1 cells drive MS inflammation, but it was shown that Th17 
cells were able to induce EAE following adoptive transfer, whereas Th1 cells failed to induce 
EAE. Moreover, antibody-mediated neutralisation of IL-17 reduced the severity of EAE, while 
blocking IFN- exacerbated the disease (Langrish et al., 2005). However, in another study 
simultaneous neuralisation of IL-17A and IL-17F had only marginal effects on disease outcome 
(Haak et al., 2009), demonstrating some difficulties in defining the role of Th17 cells. A possible 
explanation might be the instability and plasticity of the type 17 phenotype, as they can switch 
to IFN- production (Abromson-Leeman, Bronson, & Dorf, 2009; G. Shi et al., 2008; Srenathan 
et al., 2016). The pathogenic role of IL-17 family cytokines is linked to many autoimmune 
diseases (Jin & Dong, 2013) as it induces the generation of pro-inflammatory cytokines and 
chemokines such as IL-1, IL-6, TNF- or GM-CSF that promote the infiltration of neutrophils 
and macrophages to inflammation site (Jadidi-Niaragh & Mirshafiey, 2011; Jin & Dong, 2013).  
To cause inflammation in the CNS, autoreactive T cells need to cross the BBB after activation in 
the periphery. By using EAE, the C-C chemokine receptor (CCR) 6-dependent entry of Th17 cells 
through the choroid plexus at the beginning of the disease was revealed (Reboldi et al., 2009). 
After invasion into the CNS, they increase BBB permeability via IL-17 and IL-22 production and 
initiate a pathological immune cell infiltration including Th1, CD8+ T cells, B cells and plasma 
cells (Kebir et al., 2007). 
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Figure 3: Hypothetical view of Tc17 and Th17 cell contribution to immune responses in acute MS 
lesions  
Tc17 and Th17 cells are primed in the periphery by APCs presenting antigens that are released from the 
CNS or by cross-reactive foreign antigens. After clonal expansion they invade the CNS where re-
activation of Th17 cells leads to an increased production of inflammatory cytokines. These cytokines 
attract other immune cells, which contribute to the immune response by direct phagocytic attack on the 
myelin layer. Tc17 cells are re-activated by MHC class I-presenting glial or neuronal cells and cause 
damage by secretion of cytokines and cytotoxic molecules. Modified from (Hemmer, Cepok, Nessler, & 
Sommer, 2002). 
 
Besides Th17 cells, also IL-17-producing CD8+ T cells contribute to MS pathogenesis. It was 
shown that CD8+ and CD4+ T cells produce similar amounts of IL-17 in active MS lesions 
(Tzartos et al., 2008) and a selective enrichment of Tc17 numbers in CSF of MS patients at early 
stages were detected (Huber et al., 2013). Interestingly, transferred Tc17 cells alone were not 
able to infiltrate the CNS of EAE-resistant interferon regulatory factor (IRF)4-deficient mice 
after immunization and could not induce EAE on their own. However, transfer of CD8+ T cells 
and a subpathogenic number of CD4+ T cells together caused the onset of EAE in Irf4-/- mice, 
indicating a cooperation between both cell types (Huber et al., 2013). In addition, it was 
demonstrated that the cooperation during early stages of EAE required both, CCR6 expression 
of CD4+ T cells and the IL-17A production by CD8+ T cells. In a first step, Tc17 cells via their  
IL-17A secretion increased the pathogenicity of Th17 cells, including IL-17 production. 
Subsequently, Th17 cells were able to infiltrate the CNS CCR6-dependently in a first step and 
recruit Tc17 cells to the CNS in a second step, which was CCR6-independent (Huber et al., 
2013). This data point to the importance of Tc17 cells during the onset of EAE, as they enable 
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the infiltration of Th17 cells into the CNS in early phases of the disease by their IL-17 
production (Huber et al., 2013). 
 
2.3.3 Dimethyl fumarate in MS therapy and beyond 
Due to intense research during the last decades several drugs have been introduced for MS 
therapy (Comi, Radaelli, & Soelberg Sørensen, 2017). One of them is dimethyl fumarate (DMF), 
a fumaric acid ester that was approved by the Food and Drug Administration (FDA) and the 
European Medicines Agency (EMA) as first-line treatment of RRMS in 2013. It is marketed 
under the name Tecfidera® and approved for patients suffering from RRMS with oral 
application of 240 mg twice a day (Bomprezzi, 2015). Already since the 1990s a combination of 
DMF and ethyl hydrogen fumarates (Fumaderm®) is used for treatment of psoriasis, an 
inflammatory skin disease to which Tc17 cells are contributing (Res et al., 2010), providing 
DMF with a long record of efficacy and safety.  
A phase II clinical study in RRMS patients with a modified fumaric acid ester, BG-12, 
demonstrated a significant reduction by 69% in the number of gadolinium enhancing lesions 
after 12-24 weeks of treatment as compared to placebo (Kappos et al., 2008). A decrease of 
relapse rate and reduced progression of disability was found in a phase III clinical study (Gold 
et al., 2012). In EAE, DMF has been shown to exert neuroprotective and immunomodulatory 
effects and to improve the clinical score (Ghoreschi et al., 2011; Linker et al., 2011; Schilling, 
Goelz, Linker, Luehder, & Gold, 2006). 
MS is considered to be a T cell-mediated disease; thus, the effect of DMF therapy on 
circulating T lymphocytes is of major interest. Studies revealed that DMF decreased the 
numbers of peripheral blood lymphocyte (Fox et al., 2012; Gold et al., 2012) with 
disproportionate CD8+ T cell reduction in stable patients, who showed no radiological or 
clinical evidence of disease activity after six months of treatment (Fleischer et al., 2017; 
Spencer, Crabtree-Hartman, Lehmann-Horn, Cree, & Zamvil, 2015). In rare cases treatment 
with DMF-containing drugs Tecfidera® or Fumaderm® led to progressive multifocal 
leukoencephalopathy (PML) in patients (Ermis, Weis, & Schulz, 2013; Longbrake & Cross, 2015; 
Rosenkranz, Novas, & Terborg, 2015).  
During the last years, several studies aimed to clarify the exact mode of action of DMF in MS 
treatment, but it is still not fully elucidated. Similar to other immunomodulatory therapies, it 
became clear that DMF rather exerts a plethora of mechanisms on various cell types (Linker & 
Haghikia, 2016). Fumarates are , -unsaturated electrophilic metabolites that covalently bind 
to cysteine residues of proteins, leading to their succination that can result in inactivation 
(Blatnik, Thorpe, & Baynes, 2008). It was demonstrated that DMF exerts protective effects 
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against oxidative stress in DCs, astrocytes and neurons by induction of a nuclear factor 
erythroid 2-related factor 2 (Nrf2)-dependent antioxidant response (Ghoreschi et al., 2011; 
Linker et al., 2011; Scannevin et al., 2012). Succination and inactivation of kelch-like ECH-
associated protein 1 (Keap1) by DMF, results in the release of Nrf2 from Keap1-binding, its 
translocation in the nucleus and induction of antioxidant gene transcription. However, the use 
of an EAE model in wildtype (WT) and Nrf2-deficient mice revealed an almost similar 
protection following DMF treatment, indicating that the anti-inflammatory effects of DMF may 
occur Nrf2-independent (Schulze-Topphoff et al., 2016).  
Furthermore, DMF was shown to bind and succinate the ROS scavenger glutathione (GSH), 
resulting in a reduced antioxidant capacity and a subsequent increase of ROS in DCs, tumour 
cells, monocytes and macrophages (Ghoreschi et al., 2011; Hoetzenecker et al., 2012; Sullivan 
et al., 2013; Zheng et al., 2015). Another study reported a significant increase in cytosolic ROS 
in T cells of in MS patients after 3 months of DMF treatment (Diebold et al., 2017). Of note, 
GSH depletion and ROS accumulation induce DCs that rather produce IL-10 instead of 
proinflammatory IL-12 and IL-23, thereby indirectly rather promoting Th2 than Th1/Th17 
differentiation (Ghoreschi et al., 2011).  
As DMF is a derivative of fumarate, a metabolic intermediate of the tricarboxylic acid (TCA) 
cycle, it is not surprising that DMF can influence the metabolism of cells: beyond succination of 
KEAP1 and glutathione, DMF succinates the glycolytic enzyme glycerinaldehyde-3-phosphat-
dehydrogenase (GAPDH) in vivo and in vitro. This results in GAPDH inactivation, followed by 
the downregulation of aerobic glycolysis in macrophages and Th1 as well as Th17 cells (Sui et 
al., 2018). Activated macrophages and T cells require glycolysis for their survival, 
differentiation and effector functions (Gerriets & Kishton, 2014; Macintyre et al., 2014; 
Tannahill et al., 2013; Wang et al., 2011). In line, Kornberg et al. found suppressed IFN- and IL-
17 production in Th1 and Th17 respectively upon DMF treatment (Sui et al., 2018). A study of 
Diebold et al confirmed the suppression of glycolysis in T cells during DMF treatment in MS 
patients (Diebold et al., 2017). 
Besides succination, DMF and its metabolite monomethyl fumarate (MMF) are reported 
agonists of the G protein-coupled membrane receptor hydroxycarboxylic acid receptor 2 
(HCAR2). It was shown that DMF decreased neutrophil infiltration and demyelination of spinal 
cords in WT but not in HCA2-deficient mice, indicating that DMF mediates its therapeutic 
effects by HCA2 (H. Chen et al., 2014).  
DMF treatment also impacts B cell subsets in vivo and in vitro (Li et al., 2017). Li et al revealed 
that DMF modulates MS disease activity by reducing the phosphorylation of nuclear factor 
'kappa-light-chain-enhancer' of activated B-cells (NF-B) as well as reducing GM-CSF, IL-6 and 
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TNF- production, thereby shifting the balance between pro-and anti-inflammatory B cell 
responses (Li et al., 2017; M. D. Smith, Martin, Calabresi, & Bhargava, 2017) A reduced NF-B 
translocation into the nucleus is reported by several studies and for different cell types 
(Diebold et al., 2017; Kastrati et al., 2016; Seidel et al., 2009). 
DMF is further known to influence the hypoxia-sensitive TF hypoxia-inducible factor-1 (HIF-
1a) (Laukka et al., 2016; Zhao et al., 2014), alter histone modifications (Sullivan et al., 2013) 
and increase DNA hypermethylation by inhibition of TET enzymes that catalyse demethylation 
by converting 5-methylcytosine to 5-hydroxymethylcytosine (5-hmC) (Laukka et al., 2016; Xiao 
et al., 2012).  
Collectively, the aforementioned studies reveal the wide range of immune modulatory and 
neuroprotective effects by DMF, which affect a variety of cell types. It shows a broad 
efficiency; however, rare cases of PML require therapy control, especially during the first year 
of treatment. 
 
2.4 Signal transduction 
In order to respond to the environment, cells of the immune system have to sense 
extracellular stimuli. These signals are transmitted via surface receptors that trigger 
intracellular signalling cascades, which regulate cellular processes including transcription, 
translation and posttranslational modifications (Murphy & Weaver, 2017). The differentiation 
into distinct T cells subsets is based on signal transduction initiated by cytokine signalling, 
followed by ligand-induced activation of serine/threonine or tyrosine kinases (Kishimoto, Taga, 
& Akira, 1994). Finally, this cytokine-induced cascade regulates the cellular fate by forming a 
network of TFs (J Zhu et al., 2010). 
 
2.4.1 Signalling networks in T cell differentiation 
The differentiation in specific T cell subsets is mediated by extracellular cytokine signals that 
induce a complex network of TFs, ultimately leading to the characteristic signature of the 
respective subpopulation. For inducing and maintaining CD4+ and CD8+ T cell subsets the 
expression of lineage-specific master regulators is a central mechanism. Th1 cells are induced 
by IFN- signalling and subsequent activation of signal transducers and activators of 
transcription (STAT)4, which results in the induction of the master regulator T-box expressed in 
T cells (T-bet). T-bet maintains Th1 differentiation by several mechanisms: by inducing 
endogenous IFN- production in a positive feedback loop (Szabo et al., 2000), increasing 
sensitivity to IL-12 signalling (Mullen et al., 2001) and repressing Gata binding protein (GATA)3 
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functions and thereby suppressing Th2 differentiation (Hwang, Szabo, Schwartzberg, & 
Glimcher, 2005). The differentiation of naïve CD8+ T cells into effector CTLs is mediated by IL-2 
and IL-12 and the combined activities of the TF B lymphocyte-induced maturation protein-1 
(Blimp-1), T-bet (Joshi et al., 2007; Kalia et al., 2010; Pipkin et al., 2010; Xin et al., 2016) Id2 
(Cannarile et al., 2006) and IRF4 (Man et al., 2013; Raczkowski et al., 2013; Yao et al., 2013). 
Th2 and Tc2 cells differentiate in the presence of IL-4-mediated STAT6 activation ultimately 
leading to GATA3 expression, which promotes Th2 proliferation and prevents Th1 
differentiation (Jinfang Zhu, Yamane, Cote-Sierra, Guo, & Paul, 2006). For Th2 cells it is known 
that IL-2-induced STAT5 is required for an optimal differentiation (Cote-Sierra et al., 2004). The 
combination of IL-4 and TGF- drives Th9/Tc9 cell fate and the TF PU.1 and IRF4 regulate the 
expression of type 9 specific genes (Chang et al., 2010; Staudt et al., 2010). The master 
regulator retinoic acid-related orphan receptor (RORt) initiates the differentiation into Th17 
and Tc17 cells (Mittrücker et al., 2014; J Zhu et al., 2010). The transcriptional regulation of type 
17 differentiation is described more in detail in the following chapter. 
Despite the aforementioned classification into CD4+ and CD8+ subsets with specific master 
regulators, differentiated T cells still have the ability to de- or redifferentiate, a phenomenon 
called ‘T cell plasticity’ (Mittrücker et al., 2014; Zhou et al., 2009). 
 
2.4.1.1 Transcriptional regulation of type 17 cell differentiation 
Only a few years ago, the presence of IL-17-producing CD8+ T cells has been described in 
human and mouse (Hamada et al., 2009; Huber et al., 2009; Intlekofer et al., 2008; Kondo, 
Takata, Matsuki, & Takiguchi, 2009). Similar to Th17 cells, also Tc17 cells differentiate in 
response to IL-6 or IL-21 along with TGF- (Hamada et al., 2009; Huber et al., 2009; Yen et al., 
2009), resulting in the expression of RORt that is crucial for production of the marker 
cytokines IL-17A and IL-17F (Ivanov et al., 2006). The presence of IL-23 stabilises the 
pathogenic phenotype (Langrish et al., 2005). IL-6- and IL-21-mediated intracellular signal 
transduction induces the activation and phosphorylation of the TF STAT3 (Ivanov, Zhou, & 
Littman, 2007), which induces expression of type 17 regulators RORt, ROR and the cytokine 
IL-17A by binding to the respective promoters (Arra et al., 2017; Laurence et al., 2007; X. O. 
Yang et al., 2008; Yen et al., 2009). In line, STAT3-deficient T cells do not produce IL-17 nor 
RORt (Laurence et al., 2007; X. O. Yang et al., 2008; Zhou et al., 2007). Furthermore, STAT3 
mediates the transcription of IL-21 and IL-23R that contribute to the stabilisation of the type 
17 phenotype (Arra et al., 2017; Huber et al., 2009; Zhou et al., 2007). It was shown that IL-6 
induces the expression of IL-21, thereby supporting type 17 phenotype by a positive feedback 
mechanism (Korn et al., 2007; Nurieva et al., 2007). In addition, IL-21 induces the expression of 
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IL-23R, thus further stabilising the type 17 phenotype (Ciric, El-behi, Cabrera, Zhang, & 
Rostami, 2009). 
In addition, the TCR-induced TF IRF4 is critical for Tc17 differentiation by inducing RORt and 
ROR on the one side and restricting Eomes and Foxp3 expression on the other (Huber et al., 
2013). The absence of IRF4 results in disturbed Tc17 differentiation, demonstrating its 
importance (Huber et al., 2013). In contrast to classical CTLs, Tc17 cells are low-cytotoxic and 
express diminished levels of Eomes and T-bet (Huber et al., 2009; Intlekofer et al., 2008; 
Srenathan et al., 2016). Recently, it was shown that costimulatory cytotoxic T-lymphocyte-
associated protein 4 (CTLA-4) regulated Tc17 differentiation and stability by enhancing STAT3 
binding to the IL-17 promoter (Arra et al., 2017).   
IFN- and IL-27 signalling restricts type 17 differentiation by inducing STAT1 expression (Hu & 
Ivashkiv, 2009; Stumhofer et al., 2006). The ratio of STAT1 /STAT3 has been shown to regulate 
the type 17 fate (Peters et al., 2015). In addition, IL-2 has been shown to suppress Th17 
differentiation by STAT5 (Gilmour, Pine, & Reich, 1995) as STAT5 and STAT3 are known to 
compete at the Il17 locus of Th17 cells, leading to activation or suppression respectively  (X. P. 
Yang et al., 2011). 
 
2.4.1.2 ROS signalling in T cells 
ROS are small, highly reactive oxygen-containing molecules. For long time, they have been 
seen as exclusively harmful, causing cell damage. However, recent data demonstrate that ROS 
are essential second messengers in a multitude of immune functions, including antiviral, 
antibacterial and anti-tumour responses (Belikov, Schraven, & Simeoni, 2015; Franchina et al., 
2018; Sena & Chandel, 2012). Most intracellular ROS are generated in mitochondria in the 
electron transport chain (ETC) during the reduction of O2 to H2O (Belikov et al., 2015). 
Enzymatic or non-enzymatic antioxidant mechanisms dynamically balance ROS levels within 
the cell and protect against oxidative damage (Meister, 1983). The most abundant antioxidant 
GSH scavenges ROS by formation of oxidised glutathione disulfide (GSSG), which can be 
reversed to GSH by glutathione reductase (S. C. Lu, 2013).  
ROS produced by macrophages have been reported to exert immunosuppressive functions and 
being functional for Treg induction (Kraaij, 2010). In addition, cancer cells and tumour-
infiltrating immune cells including macrophages produce high levels of ROS in the tumour 
microenvironment, thereby suppressing T cell responses and contributing to tumour growth 
(X. Chen, Song, Zhang, & Zhang, 2016). 
TCR signalling during activation of T cells leads to a release of Ca2+ from the endoplasmatic 
reticulum. Ca2+ is taken up by mitochondria and results in elevated ETC, leading to increased 
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oxygen consumption and ROS production (Murphy & Weaver, 2017). Depending on their levels 
and localisation, ROS can influence T cell responses by altering signalling transduction and 
metabolism (Franchina et al., 2018; Sena & Chandel, 2012). It revealed that high ROS levels 
suppress T cell activity (Gelderman, Hultqvist, Holmberg, Olofsson, & Holmdahl, 2006) and 
initiate DNA damage and cell death (Sena & Chandel, 2012), whereas low ROS concentrations 
promote T cell activation, expansion and effector functions (Devadas, Zaritskaya, Rhee, 
Oberley, & Williams, 2002; Jackson, Devadas, Kwon, Pinto, & Williams, 2004). Sena et al 
showed that an ROS-dependent signalling is required for activation of nuclear factor of 
activated T-cells (NFAT) and IL-2 expression (Sena et al., 2013), thus, confirming ROS as an 
essential component for T cell activation. Furthermore, there is evidence for the ability of ROS 
to affect T cell differentiation: T cells lacking the ROS-producing enzyme NADPH oxidase 
showed diminished expression of STAT1, STAT4 and T-bet, resulting in reduced production of 
IL-2, IL-4, IFN- and TNF-, whereas STAT3, IL-17 and TGF- were elevated (Tse et al., 2010). 
These results underline the capacity of ROS to modify immune responses.  
 
2.4.1.3 IL-2 signalling in T cells 
The cytokine IL-2 belongs to the common -chain family and plays a central role in the 
regulation of tolerance and immunity (Malek & Castro, 2010). It mediates its functional activity 
by binding to the cell surface receptor complex consisting of IL-2R (CD25), IL-2R (CD122) and 
IL-2R (CD132). Interestingly, IL-2R is not expressed on resting, naïve T cells, thereby 
preventing a response to physiologic doses of IL-2 (Malek & Castro, 2010). Upon T cell 
activation IL-2R is induced and the cells become sensitive to IL-2 signalling (Boyman & Sprent, 
2012). Binding of IL-2 to its receptor leads to a conformational change that initiates the 
activation of associated cytoplasmic kinases Janus kinase 1 (JAK)1 and JAK3, which 
subsequently phosphorylate several tyrosine residues on the IL-2R chain. In the following 
steps, several IL-2 downstream pathways are induced: STAT5 is recruited and phosphorylated 
by the two tyrosine residues Tyr392 and Tyr510, leading to transcription of IL-2-dependent genes 
(Lin et al., 2012). In addition, phosphoinositide 3-kinase (PI3K) and mitogen-activated protein 
kinase (MAPK) are activated by Tyr338 and the adapter protein Shc (G. A. Smith, Taunton, & 
Weiss, 2017). Depending on the physiologic context, these three signals ultimately trigger 
proliferation, differentiation into specific T cell subpopulations and production of effector 
molecules (G. A. Smith et al., 2017). 
Functionally, IL-2 induces the expression of IL-2R on activated CD4+ and CD8+ T cells and 
stimulates their proliferation (G. A. Smith et al., 2017). Furthermore, IL-2 is essential for the 
development of Treg cells during thymic development (Cheng, Yu, Dee, & Malek, 2013; 
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Shevach et al., 2006), contributes to T memory formation (Bachmann & Oxenius, 2007; 
Williams, Tyznik, & Bevan, 2006) and terminal differentiation into T effector cells (Kalia et al., 
2010; Pipkin et al., 2010). Interestingly, strong or extended IL-2 signalling drives CTL effector 
cell differentiation, whereas weak or limited IL-2 signals enhance CTL memory cell formation 
(Kalia et al., 2010; Pipkin et al., 2010). IL-2 induces Blimp-1 that supports terminal 
differentiation of effector T cells (Cretney et al., 2011; Kallies et al., 2006; Kallies, Xin, Belz, & 
Nutt, 2009; Kallies & Nutt, 2007; Rutishauser et al., 2009), but also contributes to 
programming of memory CTLs (Feau, Arens, Togher, & Schoenberger, 2011; Williams et al., 
2006). Therefore, IL-2 signalling in CTL differentiation is complex and still incompletely 
understood (Xin et al., 2016). The other CTL-skewing cytokine, IL-12, enhances the expression 
of T-bet and Id2 (Joshi et al., 2007; X. P. Yang et al., 2011) and via phosphoinositide 3-kinase 
(PI3K)-AKT also drives the serine/threonine protein kinase mammalian target of rapamycin 
(mTOR) activity (Araki et al., 2009). Of note, the loss of both CTL-driving TF T-bet and Blimp-1 
was shown to induce a substantial IL-17 production in CD8+ T cells (Xin et al., 2016), 
demonstrating the plasticity of T cells as well as the importance of T-bet and Blimp-1 for CTL 
fate. 
Whereas CTL and Treg differentiation is supported by IL-2 signalling (Kalia et al., 2010; Pipkin et 
al., 2010; Shevach et al., 2006), IL-2 opposes Th17 cells by inducing STAT5, leading to elevated 
binding of the negative regulator to the Il17 promoter (Laurence et al., 2007).   
Despite similarities in IL-2-dependent signal transduction in CD4+ and CD8+ T cells, there are 
also differences: whereas IL-2 signalling in CD4+ T cells initiates a biphasic STAT5 
phosphorylation (P-STAT5), CD8+ T cells show a single, sustained peak of P-STAT5, indicating 
functional differences in downstream-signalling cascades in both T cell classes (G. A. Smith et 
al., 2017). Furthermore, the phosphorylation of S6, a downstream target of the PI3K/AKT and 
mTOR kinase pathway is higher in CD8+ T cells compared to CD4+ T cells (Yu, Zhu, Altman, & 
Malek, 2009).  
 
2.5 Epigenetic regulation of gene expression 
In a multicellular organism all cells contain homogeneous genetic information. However, these 
cells with the same underlying DNA sequence are extremely heterogeneous in their phenotype 
and function due to differential gene expression, which is preserved through cell division 
(Kanno, Vahedi, Hirahara, Singleton, & O’Shea, 2012). Gene expression is not exclusively 
regulated by the presence/ absence or activation of specific TFs; additionally, other factors 
contribute to the transcription of a genomic sequence. The term ‘epigenetics’ is used to 
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describe heritable changes in gene expression that do not involve changes of the DNA 
sequence (Dupont, Armant, & Brenner, 2009).  
 
2.5.1 Chromatin remodelling 
Eukaryotic DNA has to be densely packed in order to fit in the nucleus. Therefore, it is tightly  
wrapped around octamers of histones, forming structures called nucleosomes, in this way a 
10,000 to 20,000-fold compaction is achieved (Zentner & Henikoff, 2013). The close binding of 
DNA to the nucleosomes is ensured by the negatively charged backbone of the DNA and the 
positively charged histones. The properties of nucleosomes can be modified in several ways, a 
process called chromatin remodelling, thereby allowing or preventing access to the DNA. 
Several elements contribute to remodelling of chromatin, including histone tail modifications, 
DNA methylation and chromosome conformation (Kanno et al., 2012). 
 
2.5.1.1 Histone tail modifications  
More than 50 years ago, it was discovered that active gene transcription correlates with 
hyperacetylation of histones (Allfrey, Faulkner, & Mirsky, 1964). Since then a plethora of 
posttranslational histone modifications has been described, such as acetylation (Ac), 
methylation (me), phosphorylation, ubiquitination and further more (Kanno et al., 2012). Two 
opposing enzymes, histone acetyltransferases (HATs) and histone deacetylases (HDACs), are 
associated with sites of active transcription, suggesting their contribution to chromatin 
remodelling (Kanno et al., 2012; Zentner & Henikoff, 2013). Acetylation of N-terminal histone 
tails is mediated by HATs. By neutralisation of positive charges of lysine residues of the 
histones, the interaction between negatively charged DNA and nucleosomes is disturbed, 
leading to elevated accessibility of the chromatin to the transcription machinery (Zentner & 
Henikoff, 2013). On the other side, HDACs mediate the removal of acetyl groups, causing tight 
binding of nucleosomal DNA to the histones. Thus, classically HDACs are associated with 
histone deacetylation and therefore reduced transcription, whereas HATs are related to 
acetylated chromatin and active transcription (Kanno et al., 2012).  
Further regulatory elements are histone methylations. In contrast to acetylation, methylations 
do not alter the charges of the amino acid lysine. Thus, the impact of histone methylation on 
nucleosome compaction is less direct and can activate or repress gene transcription (Zentner & 
Henikoff, 2013). Whether a gene is activated or silenced is depending on the number of methyl 
groups as well as the lysine position on the histone. Methylation is known to occur on histone 
H3 (K4, K9, K27, K36) and H4 (K20) (Dimitrova, Turberfield, & Klose, 2015; Kouzarides, 2002). 
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For example, H3K4me is linked with active gene transcription, whereas H3K27me is seen as a 
repressing histone methylation (Kouzarides, 2002). 
 
2.5.1.2 DNA methylation 
DNA methylation occurs on cytosines in CG-rich regions of the DNA and is widely associated 
with gene silencing (Kanno et al., 2012). CG-rich regions, so called CpG islands, are short DNA 
sequences with a high frequency of 5’-CpG-3’ sequences. They often occur at transcription 
start sites (TSS) and are mostly unmethylated, leading to active transcription (Chatterjee & 
Vinson, 2012). The methylation of CpG islands by DNA methyltransferases was considered to 
be the most stable epigenetic mark that transfers heritable epigenetic memory (Kanno et al., 
2012). However, 10 years ago ten eleven translocation (TET) proteins were discovered, which 
are able to modify methyl cytosine and thereby probably remove DNA methylations (Tahiliani 
et al., 2009), implying that DNA methylation patterns are not as stable as previously assumed 
(Rasmussen 2016). 
 
2.5.1.3 Nucleosome compaction and chromatin conformation 
Accessible DNA is required to allow binding of the transcription machinery in order to achieve 
gene transcription. It was shown that nucleosomes can alter their position with respect to a 
specific DNA sequence, thereby reducing their occupancy at a promoter and allowing active 
transcription. This process is called nucleosome compaction and is mediated by ATP-
dependent nucleosome remodelers, multiprotein complexes that are able to slide or 
disassemble histone octamers (Kanno et al., 2012). 
In addition to histone modifications, DNA methylation and nucleosome compaction also three-
dimensional chromatin conformation has been recognised to affect regional gene transcription 
(Deng & Blobel, 2010). Chromatin looping allow close contact between distal regulatory 
elements and their respective promoter region. These interactions realised by formation of 
three-dimensional structures can take place on the same (cis) or even between regions of 
different chromosomes (trans)(Kanno et al., 2012).  
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3. Material  
 
3.1 Equipment 
Device Model Company 
Bioruptor Bioruptor® Plus Diagenode, Liège, Belgium 
Flow cytometers 
BD FACSCalibur 
BD FACSAriaIII 
BD, Franklin Lakes, USA 
Incubator HERAcell240i Heraeus, Hanau 
pH meter inoLab pH Level 2 WTW, Weilheim 
Plate photometer FLUOstar Omega BMG Labtech, Ortenberg 
qPCR machine StepOnePlusTM 
Applied Biosystems, 
Darmstadt 
 
3.2 Chemicals and consumables 
Chemical Company 
AB serum Sigma-Aldrich, St. Louis, USA 
Aqua dest. Braun, Melsungen 
Akt1/2 kinase inhibitor Merck, Darmstadt 
Biotinylated microBeads Institute for Med. Microbiology, Marburg 
Bovine serum albumin Biomol, Hamburg 
Brefeldin A Sigma-Aldrich, St. Louis, USA 
β-Mercaptoethanol Sigma-Aldrich, St. Louis, USA 
2-DG Merck, Darmstadt 
Dimethyl fumarate Sigma-Aldrich, St. Louis, USA 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich, St. Louis, USA 
DNase I Sigma-Aldrich, St. Louis, USA 
Dulbecco’s Modified Eagle’s Medium Sigma-Aldrich, St. Louis, USA 
EDTA Thermo Fisher Scientific, Waltham, USA 
Fetal calf serum Sigma-Aldrich, St. Louis, USA 
Glutathione, reduced form ethyl ester Sigma-Aldrich, St. Louis, USA 
Glycine Riedel-de Haën, Seelze 
Halt Protease Inhibitor Single Use Cocktail Thermo Fisher Scientific, Waltham, USA 
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HEPES Roth, Karlsruhe 
Incomplete Freund’s adjuvans (IFA) Sigma-Aldrich, St. Louis, USA 
Ionomycin Sigma-Aldrich, St. Louis, USA 
L-glutamine Biochrom, Berlin 
Lithium chloride Merck, Darmstadt 
Ly294002 Cell Signaling Technology, Danvers, USA 
MOG37-50 peptide 
synthesised by R. Volkmer, Charite Berlin, 
Germany 
Mycobacteria tuberculosis H37 RA Difco, Michigan, USA 
Non-essential amino acids (NEAS) 100x PAA, Pasching, Österreich 
NP-40 (Igepal-CA6309) Sigma-Aldrich, St. Louis, USA 
Pancoll (ficoll solution) Pan Biotech, Aidenbach 
para-formaldehyde 4 % Sigma-Aldrich, St. Louis, USA 
Penicillin G Biochrom, Berlin 
Pertussis toxin from Bordetella pertussis Sigma-Aldrich, St. Louis, USA 
Phorbol 12-Myristate 13-Acetate (PMA) Sigma-Aldrich, St. Louis, USA 
Phosphate buffered saline (PBS) 10x Biochrom, Berlin 
PIPES Roth, Karlsruhe 
Protein A Sepharose Beads 4 FastFlow GE Healthcare, Chalfont St. Giles, UK 
RPMI 1640 Sigma-Aldrich, St. Louis, USA 
Saponin Sigma-Aldrich, St. Louis, USA 
Streptavidin-Biotin α-FITC Institute for Med. Microbiology, Marburg 
Sodium bicarbonate (NaHCO3) Biochrom, Berlin 
Sodium chloride (NaCl) Sigma-Aldrich, St. Louis, USA 
Sodium dodecyl lsulphate (DOC) Sigma-Aldrich, St. Louis, USA 
Sodium pyruvate Sigma-Aldrich, St. Louis, USA 
STAT5-Inhibitor Cayman Chemicals, Ann Arbor, USA 
Streptomycin sulphate Biochrom, Berlin 
TEMED Sigma-Aldrich, St. Louis, USA 
Tris-Base Roth, Karlsruhe 
Tris-HCl Roth, Karlsruhe 
Triton-X 100 Sigma-Aldrich, St. Louis, USA 
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3.3 Kits and dyes 
Kit Company 
Annexin V APC Biolegend, San Diego, USA 
BD Phosflow Lyse/ Fix Buffer BD, Franklin Lakes, USA 
BD Phosflow Perm Buffer III BD, Franklin Lakes, USA 
5(6)-Carboxyfluorescein diacetate N-
succinimidyl ester (CFSE) 
Thermo Fisher Scientific, Waltham, USA 
CM-H2DCFDA Thermo Fisher Scientific, Waltham, USA 
Fast SYBR™ Green Master Mix Thermo Fisher Scientific, Waltham, USA 
FoxP3 Transcription Factor Fixation/ 
Permeabilization Concentrate and Diluent 
Thermo Fisher Scientific, Waltham, USA 
GSH/GSSG Glo™ Assay Promega, Madison, USA 
High Pure RNA Isolation Kit Roche, Basel, Switzerland 
IL17 DuoSet ELISA, murine R&D systems, Wiesbaden 
LIVE/DEAD Fixable Near-IR Dead Cell Stain Kit Thermo Fisher Scientific, Waltham, USA 
Propidium iodide Sigma-Aldrich, St. Louis, USA 
RevertAid First Strand cDNA synthesis Kit Thermo Fisher Scientific, Waltham, USA 
 
3.4 Buffers and Media 
3.4.1 Buffers and media for cell biology 
Buffer / media Composition 
Balanced Salt Solution 
9.9 g/l Hank’s Balanced Salt, 1.425 g/l NaHCO3,  
10 mM HEPES in Aqua dest. (pH 7.2) 
Coating buffer for cell culture 50 mM Tris-Base (pH 9.5) in Aqua dest. 
DMEM (complete media for cell 
culture) 
50 µM ME, 60 mg/ml Penicillin G, 100 mg/ml 
Streptomycin, 2.4 g/l HEPES, 1.4g/l NaHCO3, 10 % FCS,  
2 mM Glutamine  
Fetal calf serum Heat inactivated (30 min, 56°C) 
MACS buffer 0.5 % BSA [w/v], 2 mM EDTA (pH 8.0) in PBS 
PBS PBS powder concentrate in Aqua dest. (pH 7.2) 
PBS/ 1% FCS 1 % FCS [v/v] in PBS 
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RPMI (complete media) 
10 % FCS, 2 mM Glutamine, 1% NEAS [v/v],  
50 µM β-Mercaptoethanol, 60 mg/ml Penicillin G,  
100 mg/ml Streptomycin in RPMI 1640 
Saponin buffer 0.3 % Saponin [w/v], 2% FCS [v/v] in PBS 
 
3.4.2 Buffers and media for molecular biology 
Application Buffer Composition 
ChIP Lysis buffer I 5 mM PIPES (pH 8.0), 85 mM KCl, 0.5 % NP-40 
 
Lysis buffer II 
 
10 mM Tris-HCl (pH 7.5), 150 mM NaCl,  
1% NP-40, 1 % DOC, 1 mM EDTA 
 
Wash buffer I 
 
20 mM Tris-HCl (pH 8.0), 150 mM NaCl,  
2 mM EDTA, 0.1% SDS, 1 % Triton-X 100 
 
Wash buffer II 
 
20 mM Tris-HCl (pH 8.0), 500 mM NaCl,  
0.1 % SDS, 1 % Triton-X 100 
 
Wash buffer III 
 
10 mM Tris-HCl (pH 8.0), 1% NP-40, 1 % DOC,  
1 mM EDTA, 0.25 % LiCl 
 TE buffer  10 mM Tris-HCl (pH 8.0), 1 mM EDTA 
 Elution buffer 1 % SDS, 0.1 M NaHCO3 
 
Reversal 
crosslinking 
0.2 M NaCl, 10 mM EDTA (pH8), 40 mM Tris (pH 
7.2), 40 µg/ml Proteinase K, 20 µg/ml RNase A 
 
3.5 Antibodies 
3.5.1 Antibodies for CD8+ T cell isolation 
Epitope Conjugate Clone Company 
α-m B220 FITC RA3-6B2 Thermo Fisher Scientific, Waltham, USA 
α-m CD11b FITC M1/70 Thermo Fisher Scientific, Waltham, USA 
α-m CD11c FITC N418 Thermo Fisher Scientific, Waltham, USA 
α-m CD49b FITC DX5 Thermo Fisher Scientific, Waltham, USA 
α-m CD4 FITC 6K1.5 Thermo Fisher Scientific, Waltham, USA 
α-m Ter119 FITC TER-119 Thermo Fisher Scientific, Waltham, USA 
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3.5.2 Antibodies for cell culture 
Epitope Clone Company 
α-m CD28 Hamster IgG, 37-51 Hybridoma supernatant 
α-m CD3ε Hamster IgG, 145-2c11 Hybridoma supernatant 
α-m IFN- Rat IgG, XMG 1.2 Hybridoma supernatant 
 
3.5.3 Antibodies for flow cytometry 
 Epitope Conjugate Clone Dilution Company 
Murine α-CD4 PE RPA‐T4 1:500 
Thermo Fisher, Waltham, 
USA 
 α-CD4 V450 RM4-5 1:500 BD, Franklin Lakes, USA 
 α-CD8a APC 53-6.7 1:500 
Thermo Fisher, Waltham, 
USA 
 α-CD8a V500 53-6.7 1:500 BD, Franklin Lakes, USA 
 α-CD44 PE IM7 1:1000 BD, Franklin Lakes, USA 
 α-CD62L AlFl 700 MEL-14 1:500 BD, Franklin Lakes, USA 
 α- Eomes APC 
Dan11ma
g 
1:500 
Thermo Fisher, Waltham, 
USA 
 α-IFN- APC XM61.2 1:500 Biolegend, San Diego, USA 
 α-IL-17A PE eBio17B7 1:500 
Thermo Fisher, Waltham, 
USA 
 
α-P-Akt 
Ser473 
AlFl488 D9E 1:100 
Cell Signaling, Danvers, 
USA 
 
α-P-Akt 
Thr308 
PE D25E6 1:100 
Cell Signaling, Danvers, 
USA 
 
α-P-S6 
(Ser235/236) 
AlFl488 D57.2.2E 1:500 
Cell Signaling, Danvers, 
USA 
 
α-P-STAT5 
(Tyr694) 
PE SRBCZX 5µl/ test 
Thermo Fisher, Waltham, 
USA 
 α-RORt PE B2D 1:500 
Thermo Fisher, Waltham, 
USA 
 α-T-bet PE eBio4B10 1:500 
Thermo Fisher, Waltham, 
USA 
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Human α-CD8a BV510 SK1 3µl/test Biolegend, San Diego, USA 
 α-CD4 Pacific Blue RPA-T4 4µl/test Biolegend, San Diego, USA 
 α-CD14 FITC HCD14 3µl/test Biolegend, San Diego, USA 
 α-CD45RA BV650 HI100 1µl/test Biolegend, San Diego, USA 
 α-IFN- APC 4S.B3 3µl/test Biolegend, San Diego, USA 
 α-IL-17A PE BL168 3µl/test Biolegend, San Diego, USA 
 
3.5.4 Antibodies for ChIP 
Epitope Catalogue Nr Amount for IP Company 
α-H3K4me3 39159 2.5 µg Active motif, La Hulpe, Belgium 
α-H3K27ac ab4729 2.5 µg Abcam, Cambridge, UK 
α-H3K27me3 39155 2.5 µg Active motif, La Hulpe, Belgium 
α-H4ac 06-866 5 µl Millipore, Darmstadt 
 
3.6 Cytokines 
Cytokine Company 
rh IL2 Novartis, Basel, Switzerland 
rh TGF-β PeproTech, Hamburg 
rm IL-6 PeproTech, Hamburg 
rm IL-1β PeproTech, Hamburg 
rm IL-23 R&D systems, Wiesbaden 
 
3.7 Primers 
Application Target Sequence Company 
qRT-PCR Il17a 
5‘-TTTAACTCCCTTGGCGCAAAA-3‘ 
5‘-CTTTCCCTCCGCATTGACAC-3‘ 
Metabion, 
Martinsried 
 Hprt 
5‘-CTGGTGAAAAGGACCTCTCG-3‘ 
5‘-TGAAGTACTCATTATAGTCAAGGGCA-3‘ 
Metabion, 
Martinsried 
 Ifng 
5‘-TTCTTCAGCAACAGCAAGGC-3‘ 
AGCTCATTGAATGCTTGGCG-3‘ 
Metabion, 
Martinsried 
 Rorc 
5‘-TTTGGAACTGGCTTTCCATC-3‘ 
5’-AAGATCTGCAGCTTTTCCACA-3‘ 
Metabion, 
Martinsried 
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ChIP Il17a promoter 
5‘-GAACTTCTGCCCTTCCCATCT -3‘ 
5‘-AGCACAGAACCACCCCTTT-3‘ 
Metabion, 
Martinsried  
 Il17a -5 enhancer 
5‘-CGATACTTTTCAGTGACATCCGTTT-3‘ 
5‘-TGCTGACTTCATCTGATACCCTTAGA-3‘ 
Metabion, 
Martinsried 
 
RPL32 promoter  
5‘-TCATTTCTCAGGCACATCTT-3‘ 
5‘-ACTCACCGTAAAACAGATGG-3‘ 
Metabion, 
Martinsried 
 
Il10 promoter 
5’-GCAGAAGTTCATTCCGACCA-3’ 
5’-GGCTCCTCCTCCCTCTTCTA-3’ 
Metabion, 
Martinsried 
 
3.8 Plasmids 
Plasmid Company 
pMIG-STAT3 (CSTAT3) 
CSTAT3 was provided by Dr. M. Klein (University of 
Mainz) 
pMIG-STAT5 (STAT5A1*6) STAT5A1*6 was made by E. Bothur as described 
before (Dissertation E. Bothur, University Marburg) 
 
3.9 Mice 
Mouse strain Description Company/breeding 
C57BL/6 Inbred wildtype mouse strain Charles River Laboratories 
Irf4-/- 
IRF4-deficient, on C57BL/6 
background 
Own breeding (Animal facility 
Biomedical Research Center, 
Marburg) 
2D2 
transgenic MOG35-55 specific 
TCR, on C57BL/6 background 
Own breeding (Animal facility 
Biomedical Research Center, 
Marburg) 
Tbx21-/- 
T-bet-deficient, on C57BL/6 
background 
Tbx21-/- mice were provided by Dr. 
H. Garn (University of Marburg) 
 
3.10 Cell lines 
Cell line Origin Modification 
HEK 293 Human embryonic kidney cells Transformed with adenovirus 5 DNA 
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3.11 Software 
Name Company 
Adobe Illustrator C3S Adobe Systems, San José, USA 
Flow Jo Treestar, San Carlos, USA 
GraphPad Prism 5.0 GraphPad Software, La Jolla, USA 
MS Office 2010 
(Word, PowerPoint, Excel) 
Microsoft, Redmond, USA 
StepOne Thermo Fisher Scientific, Waltham, USA 
R Studio, Bioconductor Free software 
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4. Methods 
 
4.1 Cell culture  
For this work primary murine lymphocytes from lymph nodes, spleen or central nervous 
system, human PBMCs and human embryonic kidney (HEK) 293 cells were used as indicated 
below. Primary murine lymphocytes were cultured in RMPI complete media with 10% FCS, 
while human primary cells were cultured in RPMI complete media with 5% AB serum. HEK293 
cells were cultured in DMEM complete media with 10% FCS. All cells were handled and 
cultured under sterile conditions in sterile bench and incubators at 37°C with 5% CO2. Cell 
numbers were determined by using a Neubauer counting chamber according to 
manufacturer’s instructions. 
 
4.2 Murine T cell isolation and in vitro differentiation  
C57BL/6 WT mice were purchased from Charles River Laboratory. Irf4-/-, Tbx21-/- and transgenic 
2D2 mice were bred at the animal facility of the Biomedical Research Center, University 
Marburg. All experiments were carried out in accordance to the German animal protection law 
and Regierungspräsidium Gießen. 
 
4.2.1 Preparation of lymph nodes and spleen 
To receive murine, naïve CD8+ T cells, mice were sacrificed by cervical dislocation. Thereafter 
lymph nodes and spleen were removed and stored in BSS on ice. To obtain a single cell 
suspension, the organs were crushed separately through 30 µm cell strainers and washed with 
BSS. All following washing steps were performed at 1500 rpm at 4°C for 5 min. In order to lyse 
remaining erythrocytes, the spleen pellet was treated with 5 ml NH4Cl2 for 4 min and then 
washed with MACS buffer to stop the lysis reaction. After centrifugation cells from spleen and 
lymph nodes were pooled and the total cell number was determined. 
 
4.2.2 Magnetic cell purification of CD8+ T cells 
To obtain CD8+ T cell fraction from homogenised lymph node and splenic cell suspension, 
magnetic negative cell separation was applied. During this method unwanted cell types like NK 
cells, macrophages or DC are labelled with antibodies binding to surface markers, followed by 
magnetic separation of labelled cells (non CD8+ T cells) from non-labelled CD8+ T cells. 
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Therefore, the mixed cell suspension was washed with MACS buffer and the pellet was 
resuspended with a primary FITC-conjugated antibody cocktail (2.5 µl/100 × 106 cells) directed 
against surface markers of unwanted cell populations. After incubation for 10 min at 4°C the 
cells were washed again with MACS buffer, resuspended with secondary streptavidin-α-FITC 
antibodies (1 µl/100×106 cells) and incubated for 15 min at 4°C. Thereafter the cells were 
washed twice with MACS buffer and biotinylated microbeads (30 µl/100×106 cells) were added 
and incubated on a rotator at 4°C for 20 min. Finally, the suspension was placed on a magnet 
at room temperature (RT) to separate the magnetic beads-labelled non-CD8+ T cells from non-
labelled CD8+ T cells and after 20 min the supernatant was removed carefully, washed with 
MACS buffer and resuspended in RPMI complete media. Cell purity was determined by FACS 
analysis using α-CD8 staining and was usually ≥ 90%. To obtain naïve CD8+CD62L+CD44- T cells, 
purified CD8+ T cells were either sorted subsequently or directly cultured in vitro upon 
magnetic cell separation. 
 
4.2.3 Activation and differentiation of CD8+ T cells in vitro 
T cell activation and differentiation requires three signals, which are provided by APCs and 
other cells under physiological conditions. In addition to (i) antigen-specific TCR binding to 
MHC, (ii) non-specific costimulatory signals and (iii) cytokine-induced signaling pathways are 
necessary to fully activate T cells.  
During in vitro cultivation these signals are provided by monoclonal antibodies directed against 
(i) the CD3 molecule of the TCR and (ii) the CD28 costimulatory receptor. To ensure 
differentiation into the desired subtype (iii) recombinant cytokines are added. 
After purification the cells were plated under Tc17 conditions (indicated in Table 1) in 24, 48- 
or 96-well plates (1.0/0.3/0.12×106) usually for 3 days and indicated in figure legends, if 
different. Resting periods were performed as indicated in figure legends. 
 
Table 1: Culture conditions for murine Tc17 differentiation 
 
 
 
 
 
 
 
 Murine Tc17 conditions 
α-CD3, coated 5 µg/ml 
α-CD28 0.5 µg/ml 
α-m IFN- 5 µg/ml 
rh IL-2 50 U/ml 
rh TGF- 0.5 ng/ml 
rm IL-6 30 ng/ml 
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4.3 Human T cell preparation and in vitro differentiation 
4.3.1 Isolation of human PBMC from whole blood 
To obtain human peripheral blood mononuclear cells (PBMC) from healthy control persons, a 
ficoll gradient was performed with whole blood. 60 ml of whole blood contained app. 80×106 
PBMCs. For separation, 15 ml of ficoll solution (at RT) was pipetted into a 50 ml tube, followed 
by careful addition of 35 ml whole blood on top. After centrifugation at 2000 rpm for 35 min at 
RT without brake, the PBMC ring was transferred into a fresh 50 ml tube and two washing 
steps with PBS were performed (1500 rpm, 5 min, 4°C). The cells were either stored at - 80°C 
overnight and transferred in liquid nitrogen for long-time storage or processed immediately. 
 
4.3.2 Differentiation of human CD8+ T cells  
Upon ficoll density gradient centrifugation, human PBMCs were incubated with antibodies and 
memory CD8+ T cells were sorted (CD8+CD45RA-) using a FACS AriaIII (see section 4.4.1). Like 
murine T cells, also human T cells require for full activation three signals (TCR and 
costimulatory signals as well as cytokines), indicated in Tab. 2. Cells were cultured in flat 
bottom 96-well culture plates for 4-5 days. Experiments were performed in collaboration with 
Dr. C. Zielinski from Technical University of Munich. 
 
Table 2: Culture conditions for human Tc17 differentiation 
 
 
 
 
 
 
 
4.3.3 Freezing and thawing of human PBMCs 
For freezing of PBMCs, the cell pellet was resuspended in 250 µl ice-cold RPMI complete media 
containing 5% human albumin and transferred to a cryotube. Then another 250 µl of RPMI 
complete media with 5% human albumin and 20% DMSO was added dropwise while gently 
swivelling. The tube was placed immediately in 4°C cold EtOH and put overnight to - 80°C to 
ensure mild freezing. The next day cells were transferred into liquid nitrogen. 
 Human Tc17 conditions 
α-CD3, coated 2 µg/ml 
α-CD28 2 µg/ml 
rh TGF- 20 ng/ml 
rh IL-1 20 ng/ml 
rh IL-6 10 ng/ml 
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In order to analyse frozen PBMCs, cryotubes were thawed, transferred in a 15 ml tube and 
washed (1500 rpm, 5 min, 4°C) twice with RPMI complete media containing 5% AB serum to 
remove the DMSO. For recovery, cells were rested for 2 h at 37°C, before restimulation. 
 
4.3.4 Restimulation of human PBMCs 
For analysis of frozen PBMC samples from untreated RRMS patients and 12 months after start 
of DMF treatment (240 mg orally twice a day), we thawed the PBMCs and added cold RPMI/ 
5% AB serum dropwise to a volume of 6 ml. Cells were washed twice with RPMI/ 5% AB serum 
(1500 rpm, 5 min, 4°C), followed by resting in 1 ml RPMI/ 5% AB serum at 37°C for 2h. 
Thereafter, cells were restimulated with 50 ng/ml PMA and 1 µg/ml ionomycin and incubated 
for 2.5 h at 37°C. After addition of brefeldin A for another 2.5 h, cells were washed with PBS 
and surface staining was performed as indicated in 4.4.2 for 30 min at 4°C. Upon fixation with 
2% para-formaldehyde, cells were stained intracellularly as mentioned in 4.4.3 for 45-60 min at 
4°C. Thereafter cells were analysed using FACS AriaIII. 
 
4.4 Flow cytometry 
Flow cytometry allows simultaneous multiparametric analysis of heterogenous cell 
suspensions as well as sorting of certain cell populations. Therefore, single cells suspended in a 
liquid stream are passed through a laser light beam and the interaction with the light is 
measured by an electronic detection apparatus as light scatter and fluorescence intensity. This 
gives information about cell size and granularity, cell viability and expression of fluorescence 
dye-labelled epitopes based on antibody binding or transfection. Cells were measured on FACS 
Calibur using CellQuest (version 0.3) or FACS AriaIII using Diva software (version 8.0.2.) and 
analysed with FlowJo Software. 
 
4.4.1 Cell sorting 
Fluorescence-activated cell sorting (FACS) enables sorting of desired cell populations based on 
respective parameters, like surface markers or intracellular amines in dead cells. 
After labelling the cell suspension with antibodies directed against surface markers, primary 
naïve CD8+CD62L+CD44- T cells were sorted by charge into separate vessels. Therefore, the 
cells were washed with PBS and incubated for 10 min at RT with LIVE/DEAD Fixable Near-IR 
Dead Cell Stain Kit to label dead cells. After washing the cells with PBS, they were incubated 
with appropriate surface antibodies for 15 min at 4°C, washed and resuspended in a suitable 
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volume of PBS/1% FCS for sorting procedure. Sorting was performed under sterile conditions 
at FACS AriaIII. Analysis usually confirmed a sorting purity of ≥ 98%. 
 
4.4.2 Surface staining 
Cells express distinct surface markers that give information about cell type, subsets and 
biological function. Additional staining of dead or dying cells with amine-reactive dyes was 
used to determine viability of the cells. 
Surface molecules are stained prior to any fixation and can be analysed without fixation. 
Therefore, cells were washed with PBS and stained with LIVE/DEAD Fixable Near-IR Dead Cell 
Stain Kit according to manufacturer’s information for 10 min at RT to determine dead or dying 
cells, then again washed with PBS. Murine cells were stained with respective antibodies in PBS 
for 15 min at 4°C in the dark, while human PBMCs were stained for 30 min. After an additional 
washing step with PBS/1%FCS cells were analysed or subjected to further staining procedures. 
 
4.4.3 Intracellular staining 
To analyse cytokine production, cells have to be restimulated. Therefore, cells were incubated 
with PMA and ionomycin to increase TCR signalling, whereas the addition of brefeldin A blocks 
the protein transport from endoplasmatic reticulum to golgi apparatus to enrich produced 
cytokines within the cell. Furthermore, cells were fixed with formaldehyde to crosslink 
proteins, followed by permeabilisation to access intracellular molecules. 
Therefore, murine cells were washed with PBS, resuspended in 1 ml restimulation medium 
containing 50 ng/ml PMA, 1 µg/ml ionomycin and 50 µg/ml brefeldin A and incubated for 4 h 
at 37°C. Then, cells were washed with PBS and fixed with 0.5 ml 2% para-formaldehyde for 20 
min at RT. After fixation, cells were washed with PBS/1% FCS and saponin buffer, followed by 
antibody incubation for 15 min for murine cells, whereas human PBMCs were stained for 45-
60 min at 4°C. For this, fluorescence-labelled antibodies in saponin buffer were added to the 
cells in a final volume of app. 150 µl. Upon incubation were washed with saponin buffer and 
PBS/1% FCS, resuspended in PBS/1% FCS and subsequently analysed. 
 
4.4.4 Intranuclear staining 
To analyse the expression of nuclear proteins and TFs the nuclear membrane has to be 
permeabilised, which requires a harsher fixation method. 
Therefore, the cells were washed in PBS and fixed with 0.5 ml 1x FoxP3 Transcription Factor 
Fixation/Permeabilization Kit for 20 min at 4°C.  
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If cells were additionally transduced with GFP-expressing vectors, cells were previously fixed 
with 0.2 ml 0.5% formaldehyde for 5 min to prevent leakage of cytoplasmic GFP and then 
washed with PBS, followed by fixation with FoxP3 Transcription Factor Fixation/ 
Permeabilization Kit.  
After fixation, cells were washed with PBS/1% FCS and saponin buffer, followed by antibody 
staining in a volume of app. 150 µl for 20 min at 4°C. Finally, cells were washed with PBS/1% 
FCS and saponin buffer and analysed by flow cytometry. 
 
4.4.5 Phosflow 
The detection of phosphorylated proteins requires a harsh and highly optimized fixation and 
permeabilisation. Therefore, the cells were washed with PBS, fixed with 1x BD Phosflow Lyse/ 
Fix Buffer and permeabilised with BD Phosflow Perm Buffer III according to the manufacturer’s 
specifications. 
 
4.4.6 ROS staining 
Measuring ROS levels within a cell was performed by usage of CM-H2DCFDA, an indicator of 
free ROS. After passive diffusion into the cell, acetate groups of CM-H2DCFDA are cleaved by 
intracellular esterases. Subsequent oxidation by ROS results in DCF, a highly fluorescent 
compound, which allows measurement by flow cytometry. 
Prior to staining, cells were washed with PBS and the cells incubated in 500 µl of 1µM CM-
H2DCFDA loading solution in PBS for 10 min at 37°C. Thereafter cells were washed twice with 
PBS, after the last wash step the pellet was resuspended in 500 µl RPMI and incubated for 15 
min at 37°C for recovery. After a final wash step with PBS/1% FCS, cells were subsequently 
analysed. 
 
4.4.7 Proliferation and apoptosis staining 
For assessment of proliferation, CD8+ T cells were isolated (see section 4.2) and incubated for 8 
min with 5µM 5(6)-Carboxyfluorescein diacetate N-succinimidyl ester (CFSE) staining solution 
at 37°C. Then, cells were washed and cultured under Tc17-driving conditions with DMSO, DMF 
or DMF in combination with GSH for 3 days. Proliferation was analysed by flow cytometry.  
For assessment of apoptosis cells were stained with Annexin V and propidium iodide. Annexin 
V binds to phosphatidylserine (PS), which is located on the cytoplasmic surface of the cell 
membrane in viable cells. However, in intermediate stages of apoptosis, PS is translocated to 
the outer leaflet of the membrane and can be bound by Annexin V, leading to a fluorescence 
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signal that can be analysed by flow cytometry. Simultaneous staining with propidium iodide, a 
DNA intercalating dye that cannot cross the membrane of living cells, allows measurement of 
apoptotic and dead cells.  
Tc17 cells were differentiated for 3 days, washed with PBS and stained with Annexin V dye and 
propidium iodide according to the manufacturer’s instructions and analysed by flow 
cytometry. 
 
4.5 Retroviral overexpression 
Retroviral overexpression of CD8+ T cells allows the functional analysis of specific TFs. First, 
HEK 293 cells are transfected with a plasmid containing the coding sequence of the gene of 
interest, usually tagged with GFP to track the expression. The transfection process takes 
advantage of the ability of retroviruses to integrate into genomic DNA and be stably expressed. 
Upon calcium-phosphate-mediated transfection, HEK cells release virus-like particles (VLPs), 
expressing the protein of interest in a massive amount. In order to transfect murine primary T 
cells with VLP-containing supernatant coding for the gene of interest, a murine stem cell 
retroviral expression system was used. 
 
4.5.1 Transfection of HEK 293 cells 
Transfection is the process of introducing nucleic acids into eukaryotic cells. This can be 
realised with a calcium-phosphate transfection method, which is based on forming calcium-
phosphate DNA precipitates. Positively charged calcium-phosphate facilitates the binding to 
the negatively charged backbone of DNA, allowing the DNA to enter the cell by endocytosis. 
One day before transfection, 1.5-2×106 HEK 293 cells were plated in a 10 cm2 petri dish. 
Transfection was performed by generating calcium-phosphate DNA precipitates by mixing 106 
µl 2 M CaCl2, respective amount of DNA (3 µg each of the packaging elements pECO and pCPG 
and 14 µg retroviral vector) and Aqua dest. to a total volume of 850 µl. In the end, 850 µl of 
HBS (pH 7.05) were added dropwise while reverse pipetting constantly to create air bubbles 
and thereby ensure fine precipitate. After incubation for 10 min at RT, DMEM media of HEK 
cells was exchanged and the transfection mix was added dropwise to the plate. The 
transfected cells were incubated for 8 h at 37°C to allow endocytosis of calcium-phosphate 
DNA precipitates. Thereafter, the transfection mix was removed by washing the cells twice 
with BSS and replaced by 5 ml prewarmed RPMI complete media. 
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4.5.2 Generation of virus-containing supernatant 
After transfection of HEK 293 cells, they release virus-like particles (VLP) to the supernatant, 
which are able to transfect other cells with the gene of interest.  
Therefore, transfected HEK 293 cells were washed and RPMI complete media was added, as 
described in 4.5.1. 24 h after transfection, the VLP-containing supernatant was transferred to a 
new tube, 5 ml of fresh RPMI complete media was pipetted to the cells and collected 48 h 
post-transfection. Both virus-containing supernatants (24 h and 48 h) were pooled, 
centrifuged, aliquoted and stored at - 80°C. 
 
4.5.3 Spin-based transduction of T cells 
In comparison to HEK 293 cells, the calcium-phosphate method is less appropriate to introduce 
the gene of interest in murine primary T cells as these cells are hard to transfect. Therefore, a 
murine stem cell retroviral expression system was used. 
T cells were isolated as described in 4.2, plated in a 48-well plate with 0.3×106 cells per well 
and centrifugated to ensure sticking to the plate bottom. In the meantime, a transduction mix 
was prepared, containing 400 µl viral supernatant containing the gene of interest, 7µg/ml 
polybrene to enhance transduction efficiency and 50U/ml rh IL-2 to ensure cell survival. Upon 
centrifugation, the media was removed completely and replaced by the transduction mix. 
Thereafter, the T cells were transduced by a centrifugation process at 2700 rpm at 37°C for 90 
min. The viral supernatant was discarded afterwards and replaced by a Tc17 differentiation 
mix. To increase the efficiency of the spin-based transduction, the process was repeated for a 
second time after 2 h of incubation. Thereafter, cells were incubated under Tc17-driving 
conditions (see section 4.2.3) for 3 days. On day three, cells were washed and rested in RPMI 
complete media containing 50 U/ml rh IL-2 and 5 µg/ml anti-mIFN- for 3 days. Thereafter, 
cells were re-cultured under Tc17 conditions for additional 72 h, then washed, restimulated 
and analysed by flow cytometer (see section 4.4). 
 
4.6 Protein-biochemical methods 
4.6.1 Enzyme-linked immunosorbent assay 
Sandwich enzyme-linked immunosorbent assay (ELISA) was performed in collaboration with 
Dr. C. Zielinski from TU Munich.  
ELISA is a plate-based assay technique designed for detecting and quantifying proteins, like 
cytokines. Briefly, a first antibody is coated to a 96-well plate, followed by incubation with the 
sample solution. Then, a second detection antibody is added, which is conjugated to an 
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enzyme that induces a horse radish peroxidase-mediated colour change. By comparing the 
colour intensity of the sample to a dilution series of a protein with known concentration, the 
protein concentration of the sample can be calculated. 
Cell culture supernatant was collected and human IL17 DuoSet ELISA was performed as 
described in the manufacturer’s specifications.  
 
4.7 Molecular biological methods 
4.7.1 Quantitative real-time PCR 
Quantitative real-time polymerase chain reaction (qRT-PCR) allows the analysis of 
transcriptional efficiencies. Beforehand total RNA has to be isolated and reversely transcribed 
into cDNA, following qRT-PCR. Thereby, the amplification of the targeted gene can be 
monitored in real-time using SYBR Green intercalation. To evaluate the relative mRNA 
expression, the threshold cycle (Ct) of the target gene is normalized to a housekeeping gene 
(∆Ct) and compared with a control condition (∆∆Ct).  
In a first step, 2-8×105 cells were washed twice with PBS and resuspended in 200 µl PBS, 
followed by RNA extraction with High Pure RNA Isolation Kit, which was used accordingly to 
manufacturer’s instructions.  
Subsequently, cDNA synthesis was performed to reversely transcribe cDNA from the RNA 
template. Herefore, 11 µl of RNA was transcribed using Oligo-dT primers on basis of the 
RevertAid First Strand cDNA synthesis Kit, according to manufacturer’s specifications. The 
resulting cDNA was diluted with Aqua dest. and used for qRT-PCR with Fast SYBR™ Green 
Master Mix on a StepOnePlus Real-Time PCR system. 
Thermocycler conditions consisted of an initial denaturation step at 95°C for 1 min, followed 
by 35 cycles of a two-step PCR program consisting of 95°C/ 3 sec and 60°C/ 30 sec. Melting 
curves were included to determine primer specificity. Ct values were analysed for gene 
expression by using the ∆∆Ct method. 
 
4.7.2 RNA sequencing 
RNA-Seq is an approach to transcriptome profiling that reveals the complete set of transcripts 
and their quantity in a cell. The sequencing process starts with the preparation of a library. For 
that RNA is isolated, transcribed to cDNA and sheared into short fragments. These fragments 
are size-selected and oligo-adaptors are ligated at both ends. In a second step, the adapter-
ligated library is loaded onto a flow cell with adaptor-complementary oligos on its surface, 
leading to DNA fragment hybridisation to the flow cell. The library is then clonally amplified, 
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resulting in cluster generation around the initial copy of fragment. In a third step, clusters are 
sequenced similar to Sanger sequencing, with a reversible terminator-based detection of single 
nucleotides. In a final step, sequenced reads are aligned to the reference genome, allowing 
data analysis. 
RNA-Seq was performed in cooperation with Dr. M. Klein and Dr. F. Marini from University of 
Mainz. Therefore, 5×105 naïve CD8+ T cells were differentiated to Tc17 cells (see Table 1) for  
48 h, washed twice with PBS, resuspended in Trizol and RNA was isolated according to 
manufacturer’s specifications. Determination of RNA quality was assessed on a Bioanalyzer 
2100 using an RNA 6000 Nano chip, whereas RNA quantification was performed on a Qubit 2.0 
fluorometer. In the next step, libraries were prepared with 300 ng RNA (RNA integrity number 
> 9) on the basis of NEBnext® ultra™ RNA Library Prep Kit for Illumina. The following 
sequencing was performed on a HiSeq2500. 
 
4.7.3 Chromatin immunoprecipitation 
Chromatin immunoprecipitation (ChIP) is used to analyse the interaction of proteins with 
DNAat specific genomic regions in primary T cells, as well as examination of histone 
modifications. Cells are first fixed to stabilise protein/DNA interactions reversibly (crosslinking) 
and lysed in a second step. Then, chromatin is subsequently sheared using sonication, followed 
by immunoprecipitation (IP) of cross-linked DNA fragments with appropriate specific 
antibodies. After removal of crosslinks, DNA is purified and qRT-PCR is performed to analyse 
the abundance of a particular DNA sequence. The enrichment of the DNA-Sequence is 
expressed as fold enrichment above background enrichment of a non-specific antibody 
control. 
 
4.7.3.1 Cell lysis, fixation and shearing 
For analysing histone modifications in primary T cells, 2-5×106 Tc17 cells were harvested, 
washed twice with PBS and transferred to a sonication tube. For crosslinking, cells were fixed 
with 1 ml of 1% formaldehyde at RT for 3 min. Fixation was stopped by adding 100 µl 1.25 M 
glycine and subsequent rotation for 30 min at RT. Thereafter, cells were pelleted (8000 g,7 
min, RT) and washed twice with cold PBS. After resuspending the cells in 1 ml lysis buffer I 
complete to disrupt cell membranes, they were either stored at -80°C or processed 
immediately. 
To obtain DNA fragments, cells were sheared by sonication. Herefore, 75 µl of lysis buffer II 
complete with 4 % SDS was added for 5 min at RT to disrupt nuclear membranes and release 
chromatin. To dilute SDS content, 225 µl of lysis buffer II complete 0% SDS were added to the 
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nuclei, followed by incubation on ice for 3 min. Then the tubes were inserted into a Bioruptor 
and 28 cycles of sonication were performed at high power intensity for 30 secs on/ off each to 
obtain 200-500 bp DNA fragments. Subsequently, samples were diluted by adding 1.2 ml lysis 
buffer II 0.1% SDS and pelleted (15000 g, 15 min, 4°C). 1.3 ml of the chromatin was stored at 
4°C for immunoprecipitation, whereas the remaining 200 µl were used to determine shearing 
efficiency. Herefore, chromatin was incubated with reversal crosslinking solution for 3 h at 
55°C, followed by incubation at 65°C overnight. By adding 750 µl 100 % of ice-cold EtOH and 30 
µl 3 M sodium acetate and centrifugation at 15000 g for 15 min at 4°C chromatin was 
precipitated. Supernatant was removed and chromatin visualized with 1 ml 75 % EtOH and 2 µl 
glycogen. After further centrifugation, the chromatin pellet was first dried and then 
reconstituted in 20 µl Aqua dest. 4 µl of loading dye were added before running the DNA on a 
1.5 % agarose gel at 80 V for 1.5 h. If sonication was successful, the stored chromatin was 
further processed. 
 
4.7.3.2 Precipitation and elution 
Protein A-coupled sepharose beads were used for immunoprecipitation, as they are able to 
bind heavy chains of antibodies, allowing a selective purification of target protein-bound DNA 
fragments. Therefore, they were washed twice with 5 ml of lysis buffer II 0.1 % SDS (3000 g, 3 
min, 4°C) and blocked with 600 µl BSA and 1 % fish skin gelatine in 5 ml lysis buffer II 0.1 % SDS 
overnight to prevent unspecific protein binding. The next day, blocked beads were washed 
again with 5 ml lysis buffer II 0.1 % SDS (3000 g, 3 min, 4°C) and divided into three different 
tubes: 
App. ½ of the blocked beads was stored at 4°C for the actual immunoprecipitation. 
App. ¼ of beads were used for preclearing I. Therefore, 20 µl blocked beads per IP were 
incubated together with chromatin for 2 h on a rotator to get rid of DNA/protein complexes 
that unspecifically bind to the beads. 
App. another ¼ was used for preclearing II by adding 1 µl of unspecific IgG antibody per IP for 1 
h at 4°C on a rotator in order to prevent unspecific IgG binding. 
After 1 h of preclearing II, the beads were washed thrice with 5 ml lysis buffer II 0.1% SDS 
(3000 g, 3 min, 4°C) and split into fresh tubes (20 µl per IP). Precleared chromatin (from 2) was 
centrifuged (8000 g/ 5 min/ 4°C) and transferred to the tubes with IgG-precleared beads and 
subsequently incubated on a rotator for another 2 h at 4°C. 
After following centrifugation (8000 g, 5 min, 4°C), the chromatin was divided into fresh tubes 
for immunoprecipitation. Therefore, the total volume of 1.3 ml was split in accordance to the 
number of IPs, an IgG control and non-precipitated chromatin, called ‘input’. The input made 
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up 10 % of the volume for IP samples and was stored at 4°C. 2.5-5 µg of specific antibody was 
added to the IP samples, whereas 0.4 µg unspecific IgG antibody was added to the control IP. 
The antibody binding was performed at 4°C on a rotator overnight. On the following day the 
antibody-bound chromatin was incubated together with 30 µl blocked beads (from 1) per IP on 
a rotator at 4°C for 2 h.  
In order to remove non-specific bound chromatin, the immunoprecipitated complexes were 
washed by adding 1 ml of ice-cold buffers with increasing salt concentrations, including twice 
washing buffer I, twice washing buffer II, thrice washing buffer III and twice TE buffer (8000 
rpm, RT, 2 min). Thereafter, samples were eluted by adding 500 µl of freshly prepared elution 
buffer, vortexing and incubation on a rotator at RT for 30 min. After centrifugation, the 
chromatin was transferred to a fresh tube and the protein-DNA crosslinking was reversed by 
adding proteinase K-containing crosslinking reversal buffer. Also, the ‘input’ samples were 
filled up to 500 µl with elution buffer before adding crosslinking reversal buffer. Then, all 
samples were incubated at 55°C for 3 h followed by a 65°C incubation overnight. 
 
4.7.3.3 DNA purification and quantitative detection 
In order to perform qRT-PCR, DNA had to be purified. Therefore, a silica membrane-based 
technique was used, as nucleic acids bind to silica membrane depending on salt concentrations 
and pH. By using QIAquick PCR Purification Kit, the precipitated DNA was diluted in 2.5 ml of PB 
buffer and 700 µl of the sample were successively transferred to the column and centrifuged 
(13000 rpm, 1 min, RT). After loading the sample completely, the column was washed by 
adding 500 µl of PE buffer and dried afterwards by centrifugation at 13000 rpm at RT for 2 min. 
To elute purified DNA, 50 µl of elution buffer were applied to the column, and after incubation 
for 10 min at 55°C, the sample was centrifuged (13000 rpm, 1 min, RT). The eluted DNA was 
stored at 4°C and used for qRT-PCR by using Fast SYBR™ Green Master Mix according to 
manufacturer’s specifications. qRT-PCR was performed on the Thermocycler StepOnePlus with 
an initial denaturation step at 95°C for 10 min, followed by 35 cycles of a three-step PCR 
program consisting of 95°C/ 30 sec, 55°C/ 30 sec and 72°C/ 20 sec. Melting curves consisting of 
95°C for 15 sec, 55°C at 1 min and 95°C for 15 sec were included to determine primer 
specificity. 
 
4.7.4 Glutathione assay 
Glutathione is the most important ROS scavenger within a cell. Most glutathione exists in the 
reduced form (GSH) to detoxify ROS and only a small percentage of glutathione is oxidised 
(GSSG) and present as a dimer of two of the peptide elements connected by a disulfide bond. 
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Changes in levels of GSH or GSSG can provide information about cell health, with low 
GSH/GSSG ratio indicating oxidative stress. To detect and quantify total glutathione (GSH and 
GSSG), GSSG levels and GSH/GSSG ratios the GSH/GSSG-Glo™ Assay was used. Briefly, cells are 
lysed and GSH and GSSG are determined, based on a GSH-dependent conversion of a GSH 
probe to luciferin. The luminescent signal is proportional to the amount of GSH. To measure 
total glutathione, all glutathione (GSH and GSSG) is converted to the reduced form, whereas 
the oxidised form is measured in a second configuration by adding a reagent that blocks all 
GSH while leaving GSSG intact. In a second reducing step, GSSG is converted to GSH for 
quantification in the luminescent reaction.  
CD8+ T cells were isolated as described in section 4.2 and cultured in Tc17-driving conditions 
for the indicated time. Thereafter cells, were washed with PBS and seeded in a 96-well ELISA 
plate with 0.3×106 cells per well. Centrifugation at 1500 rpm for 5 min was performed to 
ensure sticking to the plate bottom, thereafter supernatant was removed and GSH/GSSG-Glo™ 
Assay was used according to the manufacturer’s instructions. 
 
4.8 Experimental autoimmune encephalomyelitis mouse model 
Experimental autoimmune encephalomyelitis (EAE) is the most commonly used animal model 
to examine human inflammatory demyelinating diseases of the CNS, like MS. EAE induction is 
facilitated by the transfer of T cells, that are specific for myelin-associated autoantigens and 
simultaneous application of MOG-peptide, pertussis toxin and Mycobacteria tuberculosis 
together with incomplete Freund’s adjuvans (IFA) to enhance the immune response and 
ensure activation and migration of disease-mediating T cells into the CNS. 
 
4.8.1 Oral DMF application and EAE induction 
Oral DMF application and EAE induction was performed in collaboration with Dr. F. Kurschus 
from University of Mainz. 
For induction of EAE, C57BL/6 or SJL/L mice were immunized s.c. at the tail basis with 50 μg 
MOG35-55 (C57BL/6) or 100 µg PLP139-151 peptide (SJL/L) emulsified in complete Freund’s 
adjuvant (CFA) supplemented with 10 mg/ml of heat-inactivated M. tuberculosis (strain 
H37RA). Along with immunisation and on day 2 post immunisation, 100 ng pertussis toxin in 
PBS was administered by i.p. injection. Oral DMF treatment was applied by supplying the 
drinking water with 0.5 mg/ml DMF starting 10 days before EAE induction during the entire 
course of the disease. Daily clinical scoring of EAE symptoms was conducted as follows: Score 
0, no symptoms, normal behaviour; Score 1, tail paralysed; Score 2, impaired righting reflex 
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and gait; Score 3, partial hind limb paralysis; Score 4, hind legs completely paralysed; Score 5, 
tetraparesis; Score 6, dead. Draining lymph nodes (dLN), spinal cord and brain were analysed 
at peak of disease (day 14–17 after immunization). 
 
4.8.2 T cell adoptive transfer and induction of EAE 
For transfer experiments, CD8+ T cells were differentiated under Tc17 conditions for 4 days in 
vitro before 6×106 cells were injected i.p. together with 1×104 antigen-specific CD4+ 2D2 cells 
into EAE-resistant Irf4-/-recipient mice (d-1). On the following day (d0) EAE was induced by s.c. 
injection of 200 µl emulsion consisting of incomplete Freund’s adjuvans (IFA), 200 µg MOG37-50 
peptide and 500 µg M. tuberculosis (strain H37RA) in the two flanks of the mice (injection of 
100 µl at each side). At the same day, 200 ng pertussis toxin in 100 µl PBS was injected i.p. to 
promote opening of the blood-brain barrier and allowing reactive T cells to migrate into the 
CNS. Pertussis toxin injection was repeated similarly on d2 upon EAE induction. Thereafter, 
mice were inspected at least daily and EAE scoring was performed. The following classification 
was applied: Score 0: healthy, no symptoms; Score 1: flaccid tail; Score 2: paralysed tail; Score 
3: hind limp weakness, ataxia; Score 4: partial hind limb paralysis. As soon as the mice were 
scored with 4 they were sacrified, CNS and dLN were removed and infiltrating T cells were 
isolated and processed. 
 
4.8.3 T cell isolation from CNS  
Isolation of T cells from lymph nodes was performed as described in section 4.2, whereas the 
isolation of T cells from CNS required a more complex conduction. Therefore, the head and 
waist of the mouse had to be removed allowing removal of spinal cord. By means of a syringe 
filled with PBS, spinal cord was rinsed out of the spine into a petri dish. Brain and spinal cord 
were crushed by scalpel and transferred into RPMI complete media containing 0.5 mg/ml 
collagenase D and 10 µg/ml DNase I. After digestion on a shaker at 37°C for 45 min, tissue was 
crushed through a 70 µm cell strainer and washed with RPMI media. To enrich lymphocyte 
fraction, the cell solution was applied to ficoll gradient centrifugation. Therefore, cells were 
resuspended in 5 ml of 40 % ficoll solution and pipetted on 3 ml of 70 % ficoll solution. Upon 
centrifugation at 620 g, w/o brake at RT for 30 min lymphocyte fraction was transferred in a 
fresh tube and washed twice with RPMI media. Then, cell number was determined as 
described in 4.1 and cells were restimulated and stained as described in section 4.4.2 and 
4.4.3. 
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4.9 Bioinformatical analysis of RNA sequencing  
Bioinformatics is an interdisciplinary field that provides important practical software tools to 
interpret and analyse high-throughput RNA sequencing data and was performed in 
collaboration with Dr. F. Marini from University of Mainz.  
To analyse differential gene expression, alignment of sequenced reads, mapping to a reference 
genome and annotation of genes was performed. By using FastQC and QoRTs (Quality of RNA-
Seq Toolset) (Hartley & Mullikin, 2015), RNA quality was evaluated.  
 
4.9.1 Alignment, mapping and annotation 
Reads were aligned and mapped to mouse reference genome (Mus musculus GRCm38). 
Corresponding gene annotation referred to ENSEMBL v76 and STAR aligner (version 2.4.0b) 
was used to perform mapping to reference genome.  
 
4.9.2 Differential gene expression analysis 
Differential gene expression analysis was performed to estimate the magnitude of differential 
expression between the samples, especially calculating the fold change of read counts and 
furthermore to estimate the significance of the differences. 
Differential expression analysis was performed with Bioconductor DESeq2 package (version 
1.12.3) and the pheatmap package (version 1.0.8), setting the false discovery rate (FDR) to 0.05 
or as indicated. To visualise the expression values of analysed samples, heatmaps were 
generated. Heatmaps show the colour-coded z-scores for the regularized logarithm (rlog) 
transformed and batch-corrected expression values of the most highly changed genes. Z-
scores indicate the number of standard deviations away from the mean of expression in a 
reference sample. Differential gene expression analysis was performed with the R 
programming language. 
 
4.9.3 Gene set enrichment analysis 
Broad Institute’s Gene set enrichment analysis (GSEA) was used to perform functional analysis 
of RNA-Seq data (Subramanian et al., 2005). The method derives its power by focusing on 
groups of genes that are involved in the same biological pathway or share common regulation 
or biological function. GSEA software was downloaded from the Broad institute. The hallmark 
gene set collection of the Molecular Signature Database (MSigDB) as well as published gene 
sets were used for GSEA. Genes were ranked and p value as well as FDR were calculated. 
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4.9.4 Principal component analysis 
Principal component analysis (PCA) is a classical multidimensional scaling method and was 
applied to categorise gene expression profiles (Ringnér & Ringner, 2008). Thereby it extracts 
the most important information from the data table and expresses this information as a set of 
new orthogonal variables called principal components. Thereby, this algorithm reduces the 
dimensionality of the data, while retaining most of the variation of a data set. PCA was 
performed using the pcaExplorer package. 
 
4.10 Statistics 
Data are means ±SD, unless indicated otherwise, and p values were determined by unpaired 
Students’s t test or two-way ANOVA test with Bonferroni’s post-hoc test with Prism 5.0 
(GraphPad). P values ≤ 0.05 were considered significant (*p < 0.05; **p < 0.01; ***p < 0.001), p 
≥ 0.05 not significant (ns). 
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5. Results 
 
Autoreactive IL-17-producing CD4+ and CD8+ T cells have been implicated in MS pathology and 
were detected in active areas of acute and chronic MS lesions (Kebir et al., 2007; Tzartos et al., 
2008). Hence, unravelling the mechanisms which control Tc17 cell differentiation is essential 
for future treatment options. 
One approved drug for MS is DMF (Tecfidera®) which is used for treatment of RRMS as it 
reduces disease activity and progression (Kappos et al., 2008) by various mechanisms: besides 
inducing anti-inflammatory DCs (Ghoreschi et al., 2011) and B cells (Li et al., 2017), DMF 
increases the ratio of CD4+/CD8+ T cells, indicating a major impact on CD8+ T cells (Spencer et 
al., 2015). In DCs, monocytes and macrophages (Ghoreschi et al., 2011; Hoetzenecker et al., 
2012; Sullivan et al., 2013; Zheng et al., 2015), DMF accumulates ROS by depletion of 
glutathione, the most important ROS scavenger. Not much is known on the impact of ROS on T 
cell activation and differentiation: Generally, elevated ROS levels on the one hand are able to 
support CD8+ T cell activation (Sena et al., 2013), whereas on the other hand can also 
dramatically impair T cell proliferation and function (Mak et al., 2017).  
Taking into consideration the impact of DMF-mediated ROS accumulation on Tc17 cells, we 
analysed the role of DMF on the differentiation of murine as well as human Tc17 cells and 
evaluated its influence on the onset of EAE. Furthermore, we determined the influence of 
Tecfidera treatment on CD4+ and CD8+ T cells in peripheral blood (PB) of RRMS patients by 
analysing their cytokine production before and after the first year of treatment.  
 
5.1 DMF-mediated ROS accumulation leads to a robust IL-17 suppression 
in Tc17 cells 
DMF binds to glutathione, thereby abolishing its antioxidative capacity and causing increased 
ROS levels in a variety of cells including DCs, astrocytes and tumour cells (Ghoreschi et al., 
2011; Scannevin et al., 2012; Sullivan et al., 2013). Considering the wide-ranging effects of 
elevated ROS levels together with the preferential impact on CD8+ T cells by DMF during RRMS 
treatment (Fleischer et al., 2017; Spencer et al., 2015), we evaluated whether DMF via 
elevated ROS influences Tc17 cells. 
To examine if DMF has an impact on IL-17-producing CD8+ T cells, murine wildtype 
(WT) CD8+ T cells were differentiated under Tc17 conditions in vitro and reduced GSH as well 
as oxidised GSSG contents were measured. The analysis revealed that DMF depletes the 
intracellular pool of GSH, leading to a decrease in the GSH/GSSG ratio (Fig. 1 A). Reduced GSH 
  
45 Results 
levels resulted in a significant upregulation of endogenous ROS as confirmed by staining with 
CM-H2DCFDA, a general oxidative stress indicator, and flow cytometric analysis (Fig. 1 B). The 
addition of cell-permeable reduced GSH-ethyl ester (GSH-OEt, GSH) largely restored 
intracellular GSH concentration and reversed increased ROS levels comparable to control. 
 
 
Figure 4: DMF-GSH-ROS axis stably suppresses IL-17 production by Tc17 cells 
(A - F) Murine CD8+ or CD4+ T cells were isolated and cultured in vitro under type 17 conditions (TGF- + 
IL-6 + IL-2) and treated with 0.2% DMSO (control, Ctrl) 20 µM DMF alone or together with 50 µM GSH or 
400 µM Trolox as indicated. (A) Ratio of reduced to oxidized glutathione contents was determined after 
2 h of culture. (B) Flow cytometric analysis of ROS levels by CM-H2DCFDA staining after 2 h of culture. 
Numbers in histogram represent MFI. Bars show fold ROS induction relative to control. (C) Flow 
cytometric analysis of IL-17A+ and IFN-+ CD8+ T cells after three days. Numbers in plots represent % of 
gated cells. Bars show percentages of IL-17A+ and IFN-+ CD8+ T cells. (D) Flow cytometric analysis of IL-
17A+ and IFN-+ CD4+ T cells after three days of culture. Bars show percentages of IL-17A+ and IFN-+ 
CD4+ T cells. (E) Flow cytometric analysis of ROS levels by CM-H2DCFDA staining of CD4+ T cells after 2 h 
of culture under type 17 conditions. (F) Outline of experimental strategy is depicted. To the right, flow 
cytometric analysis of IL-17A+ CD8+ T cells after six days of culture. CD8+ T cells were primed under Tc17 
conditions and treated ± DMF ± GSH for three days. Then, the cells were washed, rested in the presence 
of IL-2 as well as anti-IFN- and left either untreated or treated again with DMF ± GSH for the next three 
days. Histograms and contour plots are representative for seven (B, C) independent experiments. Bars 
show mean ± SD from three (D, E, F), five (A) or seven (B, C) combined experiments. Statistical analysis 
was performed using unpaired two-tailed Student’s t-test (ns P>0.05, * P<0.05, ** P<0.01, *** P<0.001). 
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DMF is able to suppress pro-inflammatory cytokine production in DCs (Ghoreschi et al., 2011), 
macrophages (McGuire et al., 2016) and B cells (M. D. Smith et al., 2017), demonstrating its 
immune modulatory mode of action. 
To investigate the influence of DMF-mediated ROS upregulation on the production of pro-
inflammatory IL-17, the effector cytokine of Tc17 cells, we performed intracellular staining for 
IL-17 and IFN-. DMF was able to suppress IL-17 significantly and simultaneously upregulated 
IFN- production in a ROS-dependent manner. Neutralisation of ROS with the anti-oxidants 
GSH or Trolox, a vitamin E derivative, restored cytokine levels comparable to control Tc17 cells 
(Fig. 1 C). Next, we differentiated Th17 cells in vitro and exposed them to DMF to examine 
whether DMF impacts Th17 cells, the CD4+ counterpart of Tc17 cells, by a similar mechanism. 
Surprisingly, DMF influenced neither IL-17 nor IFN- production of Th17 cells, although ROS 
were upregulated significantly (Fig. 1 D, E). To investigate the duration of the DMF-mediated 
IL-17 reduction in Tc17 cells that allows a prediction about the stability of IL-17 suppression 
during treatment, cells were primed under Tc17 conditions for three days with DMSO, DMF 
alone or in combination with GSH, followed by washing and resting in the absence or presence 
of DMF for further three days. Flow cytometric analysis revealed a stable IL-17 inhibition, as IL-
17-producing cells remained significantly reduced after the resting phase, comparable to 
continuous DMF treatment over six days (Fig 1 F).  
Hence, DMF-mediated GSH depletion resulted in an early ROS upregulation, leading to 
increased IFN- levels and a robust IL-17 suppression in Tc17 cells. 
 
5.2 IL-17 is diminished by DMF-mediated transient ROS upregulation at 
early stages of Tc17 differentiation  
DMF induces an anti-oxidant response in astrocytes (Scannevin et al., 2012), neurons (Linker et 
al., 2011) and DCs (Ghoreschi et al., 2011) by succination of Keap1 and thereby activation of 
the NRF2 pathway. After detecting elevated ROS levels in Tc17 cells upon DMF treatment, we 
thought to elucidate the compatibility between moderate accumulation of ROS on one side 
and an induction of anti-oxidative stress responses on the other.  
Therefore, the ratio of GSH/GSSG as well as ROS levels were determined 24 h post 
Tc17 differentiation and DMF treatment. Surprisingly, GSH/GSSH ratio showed an upward 
trend and ROS levels were already significantly reduced after 24 h of DMF treatment as 
compared to control (Fig. 2 A, B). In line with this finding, anti-oxidative NRF2 targets were 
upregulated in DMF-treated Tc17 cells, indicating an activation of mechanisms counteracting 
the previous ROS accumulation (Fig. 2 C). To examine whether the early ROS increase by DMF-
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mediated GSH-depletion was sufficient to restrict IL-17 production, DMF was added to the cells 
at later time points of differentiation. It revealed that only the early application of DMF after 
up to 17 h of differentiation was sufficient to suppress IL-17 production, whereas DMF hardly 
affected the already established Tc17 cells (Fig. 2 D).  
In summary, the DMF-mediated increase of endogenous ROS at early stages of Tc17 
differentiation is required for an efficient IL-17 inhibition, despite a rapid counter regulation by 
induction of oxidative stress response pathways. In contrast, DMF treatment at later time 
points of differentiation is not able to limit IL-17 production. 
 
 
Figure 5: DMF upregulates ROS transiently and suppresses IL-17 production at early stages of Tc17 
differentiation 
(A-D) WT CD8+ T cells were isolated and cultured in vitro under type 17 conditions and treated with 0.2% 
DMSO (control, Ctrl) 20 µM DMF alone or together with 50 µM GSH as indicated. (A) Ratio of reduced to 
oxidized glutathione contents was determined after 24 h of culture. (B) Flow cytometric analysis of ROS 
levels by CM-H2DCFDA staining after 24 h of culture. Numbers in histogram represent MFI. Bars show 
MFI of CM-H2DCFDA staining. (C) Expression of normalised counts of NRF2 target genes as determined 
by RNA-Seq. CD8+ T cells were cultured in vitro under type 17 conditions with indicated treatment for 
two days. Total RNA was purified and RNA-Seq was performed (n=3). (D) Flow cytometric analysis of IL-
17A+ CD8+ T cells after three days of Tc17 priming with addition of DMSO (Ctrl) or DMF at indicated time 
points after culture start. Bars show percentages of IL-17+ CD8+ T cells. Histogram in B is representative 
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for three independent experiments. (A - D) Bars show mean ± SD from three combined experiments. 
Statistical analysis was performed using unpaired two-tailed Student’s t-test (ns P>0.05, * P<0.05, ** 
P<0.01, ***p<0.001). 
 
5.3 DMF signalling suppresses IL-17 production independent of apoptosis 
or proliferation 
The positive safety record of DMF is compromised by the occurrence of lymphopenia, or in 
rare cases of PML in MS patients under Tecfidera treatment (Linker & Haghikia, 2016). To 
examine if the altered cytokine production is an effect of elevated apoptosis, Annexin V and 
propidium iodide staining was performed in Tc17 cells. 20 µM DMF, the concentration that 
significantly reduced IL-17 production, did not induce apoptosis, whereas higher DMF 
concentrations were pro-apoptotic (Fig. 3 A). Interestingly, this effect was reversed by adding 
the antioxidant GSH, confirming that DMF via ROS upregulation leads to cell death at high 
concentrations, whereas moderate ROS levels rather alter Tc17 cells fate. 
In addition, the influence of DMF-treatment on proliferation of Tc17 cells was assessed. It 
revealed that DMF-treated Tc17 cells showed a non-significant tendency towards reduced 
division as indicated by CFSE staining and flow cytometric analysis after three days (Fig. 3 B). 
However, this did not influence the IL-17 production, as the frequencies of IL-17-producing 
cells in DMF-treated samples were similarly reduced in each proliferation stage as compared to 
control (Fig. 3 C). 
 
Figure 6: DMF does not influence apoptosis or proliferation of Tc17 cells at immune modulatory 
concentrations 
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(A) Flow cytometric analysis of apoptosis via Annexin V and propidium iodide staining. CD8+ T cells were 
primed in vitro under Tc17 conditions treated with DMSO, 20 or 40 µM DMF alone or in combination 
with GSH as indicated for three days. Numbers represent % of gated cells. Bars show quantification of 
Annexin V+ Tc17 cells. (B) Flow cytometric assessment of proliferation by CFSE staining. CD8+ T cells 
were stained with CFSE, washed and primed under Tc17 conditions with indicated treatment for three 
days. Numbers in histogram represent MFI. Bars show fold changes of MFI of CFSE-stained cells. (C) Dot 
blot of CFSE-stained Tc17 cells with marking of each proliferation cycle. Bars show fold changes of IL-
17A+ CD8+ T cells at each proliferation cycle after three days of differentiation relative to control. 
Histograms and dot plots are representative for three (A - C) independent experiments. Bars show mean 
± SD from three (A - C) combined experiments. Statistical analysis was performed using unpaired two-
tailed Student’s t-test (ns P>0.05, *P<0.05, **P<0.01, ***P<0.001). 
 
  
5.4 DMF-ROS axis modifies Tc17 cell gene signature 
After having confirmed that DMF-mediated ROS suppressed IL-17 independent of apoptosis- 
and proliferation, RNA-Sequencing (RNA-Seq) was performed to examine the impact of DMF 
on Tc17 cells on a genome-wide level. In addition, principal component analysis (PCA) was 
carried out to compare genetic profiles between differently treated Tc17 cells. Furthermore, 
gene set enrichment analysis (GSEA) was performed as previously described (Subramanian, 
2005) to determine involved pathways in IL-17 suppression mediated by the DMF/ROS axis. 
In DMF-treated Tc17 cells, 994 transcripts were significantly upregulated and 898 
significantly downregulated (FDR < 0.01, as compared to control. Interestingly, most of the 
altered gene expression was restored by addition of GSH, indicating a major contribution of 
increased ROS levels to the modulation of Tc17 cells. To visualise and compare gene 
expression profiles, PCA was performed which showed a distinct gene expression between 
DMF-treated and control Tc17 cells. Interestingly, the profiles of Tc17 cells that received DMF 
in combination with GSH were similar to control cells (Fig. 4 A, B). By performing GSEA it was 
confirmed, that DMF treatment significantly downregulated Tc17-associated genes, whereas 
ROS neutralisation by GSH restored the transcriptional program comparable to control cells 
(Fig. 4 C). Amongst the 70 most significantly downregulated transcripts, several Tc17-
associated genes were found, as Il17a, Il17f, Il21, Rorc and Il21 (Fig. 4 D). In line, the main 
transcription factor of Tc17 cells, RORt, was significantly reduced on protein level in cells 
treated with DMF as compared to control, an effect that was again dependent on ROS (Fig. 4 
E). 
Taken together, these results revealed that DMF treatment via ROS controls Tc17 
differentiation by suppressing the Tc17 transcriptional program in vitro. 
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Figure 7: Tc17 fate is suppressed by DMF treatment 
(A-D) CD8+ T cells were cultured under Tc17 conditions and treated with DMSO (Ctrl), DMF alone or in 
combination with GSH for two days. RNA was isolated and RNA-Seq was performed (n=3). (A) Heatmap 
shows color-coded z-scores for the regularized logarithm (rlog) transformed batch-corrected expression 
values. Displayed are 659 differentially expressed genes with an effect size of at least > 1.5-fold (log2) 
and FDR < 0.01 in the expression between control vs DMF-treated Tc17 cells. (B) Principal component 
analysis (PCA) of Tc17 cells treated as indicated (C) GSEA comparing the relative expression of genes of 
Tc17 cells with indicated treatment, examining the distribution of genes associated with Tc17 phenotype 
as defined in GSE110346. (D) Heatmap shows color-coded z-scores for the rlog transformed batch-
corrected expression values. Displayed are the top 70 core enriched hits of genes downregulated in 
DMF-treated Tc17 cells. (E) Flow cytometric analysis of RORt levels in CD8+ T cells after three days of 
Tc17 priming and treatment with DMSO (Ctrl), DMF alone or in combination with GSH. Numbers in 
histogram represent MFI. Bars show fold MFI changes relative to DMF treatment. Histogram in E is 
representative for three independent experiments. Bars in E show mean ± SD from three combined 
experiments. Statistical analysis was performed using unpaired two-tailed Student’s t-test (ns P>0.05,  
* P<0.05, ** P<0.01, *** P<0.001). 
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5.5 DMF via ROS suppresses permissive histone modifications at the Il17 
locus 
Elevated ROS levels can modulate the activity of intracellular signalling molecules and 
pathways, including epigenetic modifications such as histone methylation and acetylation 
(Kim, Ryan, & Archer, 2013; Kreuz & Fischle, 2016).  
To evaluate whether the DMF/ROS axis suppresses IL-17 in Tc17 by affecting the epigenetic 
landscape, Tc17 cells were differentiated in vitro for three days and ChIP assays were 
performed.  
First, we compared permissive total acetylation levels of H4 as well as for H3K27 in 
Tc17 cells treated with control, DMF alone or in combination with GSH. While DMF treatment 
reduced H4Ac as well as H3K27Ac levels at the Il17 promoter and enhancer, the addition of 
GSH restored the occupancy of acetylation at both sides, indicating a ROS-dependent 
mechanism (Fig. 5 A). After having demonstrated that DMF via ROS modified histone 
acetylation, we evaluated whether ROS could impact the acetylation status of histones.  
 
 
Figure 8: DMF alters histone modifications at the Il17 locus of Tc17 cells in a ROS-dependent manner  
(A, C, D) CD8+ T cells were differentiated for 3 days under Tc17 conditions with indicated treatment and 
ChIP analysis were performed. (A) ChIP analysis for H4Ac and H3K27Ac at the Il17 promoter, Il17 
enhancer-5 and Il10 promoter. (B) Flow cytometric determination of IL-17A+ CD8+ T cells differentiated 
for 3 days under Tc17 conditions with indicated treatment. (C) ChIP analysis for H3K4me3 at the Il17 
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promoter, Il17 enhancer -5 and Rpl promoter. (D) ChIP analysis for H3K27me3 at (C) the Il17 promoter 
and Il17 enhancer -5 or (D) Il10 promoter. The experiments were repeated three times with consistent 
results. Bars show mean ± SD of fold change relative to DMF-treated Tc17 cells from three (A, C, D) or 
five (B) combined experiments. (A-D) Statistical analysis was performed using unpaired two-tailed 
Student’s t-test (ns P>0.05, * P<0.05, ** P<0.01, *** P<0.001). 
 
Histone deacetylation is catalysed by HDACs, whose activity cannot only be suppressed, but 
also increased by ROS (Kreuz & Fischle, 2016). To determine the contribution of HDACs during 
DMF-mediated IL-17 inhibition, Tc17 cells were treated with DMF together with the HDAC 
inhibitor TSA. Notably, the addition of TSA could partially restore the inhibitory effect of DMF 
on IL-17 production, indicating that the DMF/ROS axis suppressed acetylation at the Il17 locus 
via HDACs (Fig. 5 B).  
Further, it has been shown that fumarates as well as ROS are able to impact the 
methylation status of histones (Afanas’ev, 2015; Kreuz & Fischle, 2016; Sullivan et al., 2013). 
Therefore, we compared permissive methylation levels of H3K4 and methylation of H3K27, 
which is associated with transcriptional silencing, at the Il17 locus of Tc17 cells treated with 
control, DMF alone or together with GSH. We found that DMF also reduced permissive histone 
trimethylation at H3K4 (Fig. 5 C), whereas the repressive trimethylation at H3K27 was not 
significantly altered (Fig. 5 D).  
Taken together, these results imply that DMF via ROS upregulation can suppress permissive 
histone acetylation and methylation at the Il17 promoter and enhancer, whereas the 
repressive methylation H3K27me3 was not affected.  
 
5.6 DMF suppresses pathogenicity of Tc17 cells in EAE 
5.6.1 Oral DMF treatment diminishes EAE severity 
DMF is a commonly prescribed oral drug for RRMS patients. Our aforementioned data show 
that DMF treatment directly impacts the fate of Tc17 cells in vitro, which are known to 
contribute to inflammatory processes in the CNS (Huber et al., 2013). To examine whether 
orally administered DMF is able to influence Tc17 cells in vivo, we performed EAE experiments 
in collaboration with Dr. F. Kurschus from University of Mainz. 
To analyse the impact of orally given DMF, EAE was induced in WT mice by 
immunisation with MOG35-55 peptide and treated with DMF in drinking water during the course 
of disease (Fig. 6 A). In accordance with the literature (Ghoreschi et al., 2011; Linker et al., 
2011; Schulze-Topphoff et al., 2016), mice that received oral DMF treatment showed reduced 
clinical EAE symptoms as compared to the control group (Fig. 6 B). The mild disease course 
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Figure 9: Oral DMF treatment limits EAE severity 
(A) Outline of experimental strategy. WT mice were immunised with MOG35-55, CFA and M. tuberculosis 
for induction of EAE. Pertussis toxin (PTX) was injected i.p. along and on day 2 post immunisation. Mice 
were treated ± DMF in drinking water starting 10 days before EAE induction and during the course of 
disease. Analysis was performed on day 14. 
 (B) Mean clinical scores (± SEM) of MOG35-55 immunised WT mice (n=8) treated orally with control or 
DMF for 24 days. P values were calculated comparing the scores of WT mice ± DMF. (C) Flow cytometric 
analysis of IL-17A+ CD8+ T cells from the CNS of WT mice ± DMF. Bars show percentages of IL-17+ CD8+ T 
cells in the CNS. (D) Flow cytometric analysis of IL-17+ CD8+ T cells in the LNs of WT mice after EAE 
induction and oral control- or DMF-treatment as described in A. Bars show percentages of IL-17A+ CD8+ 
T cells in the LNs. Experiments were repeated three times with consistent results. Bars show mean ± SD 
from mice (n = 8) from one representative experiment. Statistical analysis was performed using 
unpaired two-tailed Student’s t-test (ns P>0.05, * P<0.05, ** P<0.01, *** P<0.001). 
during DMF treatment was accompanied by significantly reduced percentages of IL-17-
producing CD8+ T cells in the CNS (Fig. 6 C) and dLNs (Fig. 6 D).  
Hence, our data show that beside direct effects on Tc17 cells in vitro, the oral administration of 
DMF suppresses Tc17 cells also in vivo, demonstrated by diminished severity of EAE and 
reduced Tc17 cell infiltration in the CNS and draining lymph nodes (dLN).  
 
 
 
 
 
 
 
 
 
 
 
 
 
5.6.2 DMF limits pathogenicity of Tc17 cells in vivo 
Our in vitro data demonstrate that DMF treatment is able to suppress the Tc17 cell fate, 
including their ability to produce IL-17. This cytokine contributes to inflammation in the CNS 
and lesion formation by promoting the generation of pro-inflammatory cytokines and 
chemokines, which attract neutrophils and macrophages to inflammation sites (Jin & Dong, 
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2013). Furthermore, it has been shown that Tc17 cells, via their IL-17 production, support Th17 
cell-mediated pathogenicity during the onset of EAE (Huber et al., 2013). In addition, we could 
show that DMF treatment in vivo diminished clinical EAE symptoms, but it was not clear 
whether these effects directly or indirectly impact Tc17 cells. 
To analyse the functional impact of DMF-treatment directly on Tc17 cells, we 
performed T cell adoptive transfer experiments. Therefore, we transferred in vitro 
differentiated congenic control- or DMF-treated Tc17 cells together with low numbers of 2D2 
CD4+ T cells, which are transgenic for MOG-specific TCR, into EAE-resistant Irf4-/- recipient mice 
(Brüstle et al., 2007; Huber et al., 2013), followed by EAE induction (Fig. 7 A). The transfer of 
low numbers of 2D2 cells alone did not evoke disease outbreak, whereas the combination with 
control Tc17 cells induced an early onset of disease including acute clinical symptoms, as 
previously shown (Huber et al., 2013) (Fig. 7 B). The severe disease course was characterised 
by T cell infiltration of both, endogenous and transferred CD8+ T cells, into the CNS (Fig. 7 C, 
D). The transferred control Tc17 cells were detectable in dLNs and their IL-17 production was 
accompanied by higher IL-17- and IFN-- production of CD4+ T cells within the CNS. In addition, 
the mice receiving control Tc17 cells were characterised by increased percentages of IL-17-
producing CD8+ T cells in dLN and elevated percentages of IL-17-producing CD4+ and CD8+ T 
cells within the CNS as compared to the control (Fig. 7 E-I). 
In contrast, recipients of 2D2 cells together with DMF-treated Tc17 cells showed only a mild 
disease course (Fig. 7 B), which was accompanied by significantly elevated T cell numbers in 
the dLNs and reduced T cell infiltration into CNS (Fig. 7 C, D). The transferred DMF-treated 
Tc17 cells were detectable in dLNs and produced less IL-17 as compared to control Tc17 cells. 
At the same time, IL-17 and IFN- production in CNS-infiltrating CD4+ T cells was reduced as 
compared to the group that received control Tc17 cells (Fig. 7 E-I). 
In summary, DMF diminishes the co-pathogenic function of Tc17 cells in an in vivo mouse 
model for MS by suppressing their transcriptional program, suggesting a possible mechanism 
for MS. 
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Figure 10: DMF limits CNS autoimmunity by suppressing the co-pathogenic function of Tc17 cells 
(A) Outline of experimental strategy. Irf4-/- mice receiving cells as described above. EAE was induced on 
the next day by injection of MOG37-50, IFA and M. tuberculosis. PTX was injected i.p. on day 0 and 2 post 
immunization. Analysis was performed on day 15. (B-H) Analysis of MOG37-50-immunized Irf4-/- mice 
receiving 1×103 CD4+ 2D2 cells alone or together with 2.5×106 CD8+ cells in vitro differentiated for four 
days under type 17 conditions ± DMF, in the following the cells are termed Tc17 cells. (B) Mean clinical 
scores (± SEM) combining two independent experiments of MOG37-50-immunized Irf4-/- (n = 7) mice. P 
values were calculated comparing the scores of Irf4-/- mice receiving CD4+ 2D2 cells together with Tc17 
cells ± DMF. (C) Absolute T cell numbers (mean ± SD of three combined experiments, n=7) in the (left) 
CNS or (right) LN of Irf4-/- mice. (D) Number of CD8+ T cells (mean ± SD of two combined experiments, 
n=5) in the CNS of Irf4-/- mice. (E, F) Flow cytometric analysis of IL-17A+ and IFN-+ gated CD4+ and CD8+ T 
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cells in the (E) LN or (F) CNS of Irf4-/- mice. Numbers in plots represent % of gated cells (G, H) 
Percentages of IL-17A+ CD4+ or CD8+ T cells (mean ± SD of three combined experiments, n=7) in (G) LN 
and (H) CNS of Irf4-/- mice. (A-H) The experiments were repeated three times with consistent results. Dot 
plots are representative for (E, F) three independent experiments. Statistical analysis was performed 
using two-way ANOVA and Bonferroni’s post-hoc test (B) or unpaired two-tailed Student’s t-test (C, D, G, 
H) (ns P>0.05, * P<0.05, ** P<0.01, *** P<0.001). 
 
 
5.7 DMF treatment shifts Tc17 cells towards a CTL-like signature 
After having validated the modulatory effect by DMF on Tc17 genetic profile and function in 
the EAE mouse model, we evaluated how DMF shapes the transcriptional signature of Tc17 
cells in more detail.  
To identify changes on the genome-wide level we further analysed the RNA-Seq data of Tc17 
cells treated with DMSO (Ctrl), DMF alone or in combination with GSH. Amongst the 70 most 
upregulated transcripts we found CTL-associated genes as Ifng, Eomes, Gzmb, Gzmc and Tbx21 
(Kaech & Cui, 2012), whose induction was largely dependent on ROS as addition of GSH 
reversed the effect (Fig. 8 A). Furthermore, by applying GSEA we found a significant 
enrichment of CTL-associated genes in DMF-treated Tc17 cells in a ROS-dependent manner as 
compared to untreated Tc17 cells. (Fig. 8 B). This included CTL marker molecules like perforin, 
granzyme B and granzyme C (Fig. 8 C). The transcription factor T-bet (encoded by Tbx21) that 
regulates effector CTL differentiation (Kallies & Good-Jacobson, 2017) was upregulated on 
protein level by DMF treatment compared to control (Fig. 8 D).  
Taken together, these results obtained by RNA-Seq analysis and flow cytometry reveal that 
DMF-mediated ROS promotes a CTL-like signature and suppressed the Tc17 transcriptional 
program. 
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Figure 11: DMF- induced ROS favours a CTL-like gene signature 
(A) Heatmap shows color-coded z-scores for the rlog transformed batch-corrected expression values 
from the dataset described in Figure 4. Displayed are the top 70 core enriched hits of genes upregulated 
in DMF-treated Tc17 cells.  (B) GSEA comparing the relative expression of genes of Tc17 cells treated as 
indicated, examining the distribution of genes associated with CTL phenotype as defined in GSE110346. 
(C) Normalized expression counts of selected CTL-associated genes in Tc17 cells with indicated 
treatment as determined by RNA-Seq. (D) Flow cytometric determination of T-bet levels in CD8+ T cells 
after three days of Tc17 priming with indicated treatment. Numbers in histogram represent MFI. Bars 
show fold MFI change of T-bet relative to control. Histogram in D is representative for three 
independent experiments. Bars show mean ± SD from three (C, C) combined experiments. Statistical 
analysis was performed using unpaired two-tailed Student’s t-test (ns P>0.05, * P<0.05, ** P<0.01, *** 
P<0.001). 
 
 
5.8 DMF/ROS axis enhances IL-2 signalling in Tc17 cells 
The aforementioned data showed that DMF treatment of Tc17 cells leads to the accumulation 
of ROS, which is responsible for a shift of the Tc17 profile towards a CTL-like signature, but the 
underlying signalling remained elusive. In order to elucidate the molecular pathways involved 
in the suppression of Tc17 cells, the acquired RNA-Seq data was further analysed by GSEA to 
explore various signalling pathways involved. 
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Figure 12: IL-2 signalling is elevated by ROS and required for suppression of IL-17 in Tc17 cells 
(A) GSEA comparing the relative expression of genes in Tc17 cells ± DMF (left) or DMF ± GSH (right) 
from the dataset described in Figure 4. Shown is the distribution of genes involved in hallmark IL- 
2-STAT5-signaling as defined by MSigDB. (B) Flow cytometric analysis of IL-17A+ CD8+ T cells 
differentiated for three days under Tc17 conditions with indicated treatment in the presence or absence 
of 50 U/ml IL-2. (C) Flow cytometric analysis of IL-17A+ CD8+ T cells differentiated for three days under 
Tc17 conditions with indicated treatment and increasing IL-2 concentrations. (D) Ratio of reduced to 
oxidized glutathione levels in CD8+ T cells differentiated for 2 h under Tc17 conditions with indicated 
treatment in the presence or absence of 50 U/ml IL-2. (E) Flow cytometric analysis of ROS levels in CD8+ 
T cells differentiated for 2 h under Tc17 conditions with indicated treatment in the presence or absence 
of 50 U/ml IL-2 after staining with CM-H2DCFDA (fold MFI relative to control). Graph in (C) shows ± SEM 
from five combined experiments. Bars show mean ± SD from three (B, D, E) or five (C) combined 
experiments. Statistical analysis was performed using unpaired two-tailed Student’s t-test (ns P>0.05, * 
P<0.05, ** P<0.01, *** P<0.001). 
 
 
We found a significant ROS-dependent enrichment of IL-2/STAT5 signalling-associated genes in 
DMF-treated Tc17 cells, suggesting an involvement of the IL-2 pathway in the suppression of 
IL-17 production of Tc17 cells (Fig. 9 A), as previously reported for Th17 cells (Laurence et al., 
2007). To prove the dependency of DMF on IL-2 signalling, we compared the effect of DMF in 
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the presence or absence of IL-2 and found that IL-2 signalling was required for the DMF-
mediated IL-17 suppression in Tc17 cells, as DMF was not able to limit IL-17 in the absence of 
IL-2 (Fig. 9 B). The effects of IL-2 were dose-dependent, as low IL-2 amounts prevented IL-17 
inhibition, whereas high concentrations were already sufficient to suppress IL-17 without 
addition of DMF (Fig. 9 C). As expected, GSH rescued the IL-17 production, demonstrating that 
the DMF-mediated ROS upregulation led to IL-17 suppression by IL-2 signalling. Finally, to test 
whether IL-2 signalling and ROS affected each other, we performed GSH-Assay and ROS-
staining in the absence or presence of IL-2. Interestingly, we could demonstrate that neither 
GSH-depletion nor ROS accumulation were dependent on IL-2 (Fig. 9 D, E).  
Hence, DMF-induced ROS levels impinge on IL-2 signalling pathways, thereby suppressing IL-17 
production of Tc17 cells. 
 
5.8.1 DMF limits IL-17 production of Tc17 cells via STAT-5 induction  
The aforementioned results revealed that the DMF-mediated ROS accumulation enhances  
IL-2/STAT5 signalling-associated genes. It is already shown for Th17 cells, that IL-2 via STAT5 
inhibits IL-17 production by the competition with STAT3 at Il17 regulatory elements (Laurence 
et al., 2007; X. P. Yang et al., 2011). In order to evaluate the contribution of STAT5 to the DMF-
mediated IL-17 suppression in Tc17 cells, we performed retroviral overexpression of 
constitutive active STAT5 and made use of a pharmacological STAT5 inhibitor. 
 Tc17 cells were differentiated with respective treatment for 2 days in vitro, followed by 
a resting phase overnight and added IL-2 kinetically. Flow cytometric analysis of the cells 
revealed elevated phosphorylation of STAT5 in DMF-treated Tc17 cells in a ROS-dependent 
manner (Fig. 10 A). To examine whether STAT5 is able to limit the IL-17 production in Tc17 
cells, they were overexpressed with a GFP-STAT5-expressing vector (pMIG STAT5) or the 
corresponding control vector (pMIG empty). To verify that GFP and P-STAT5 expression 
correlated, staining of P-STAT5 was performed. Indeed, high levels of GFP correlated with 
enhanced production of P-STAT5 in cells transduced with the pMIG STAT5 vector, but not in 
cells transduced with pMIG empty as expected. In line, the highest P-STAT5 expression was 
detected in the highly pMIG STAT5-transduced cells (Fig. 10 B). Next, the IL-17 production of 
Tc17 cells either transduced with pMIG empty or pMIG STAT5 was determined. We found a 
significant inhibition of IL-17 in P-STAT5 overexpressed Tc17 cells as compared to cells 
transduced with the control vector (Fig, 10 C, D), indicating that P-STAT5 is able to suppress IL-
17 production also in Tc17 cells. The inhibitory effect of DMF-ROS-STAT5 pathways was at least 
partially regulated by competition with STAT3, as the IL-17 suppression by DMF was 
significantly decreased by overexpression with constitutive active STAT3 (pMIG STAT3) (Fig. 10 
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E). To link the enhanced P-STAT5 production to the DMF-mediated IL-17 suppression, we 
added a STAT5 inhibitor together with DMF to the cells and analysed the IL-17 production after 
three days of culture. Of note, the inhibition of STAT5 could only partially restore the IL-17 
production of Tc17 cells, suggesting a contribution of further IL-2 dependent pathways to the 
ROS-mediated suppression of IL-17 in Tc17 cells (Fig. 10 F). 
 
 
Figure 13: Elevated P-STAT5 contributes to the DMF-mediated IL-17 inhibition of Tc17 cells  
(A) Flow cytometric analysis of P-STAT5(Y694) in CD8+ T cells differentiated for 2 days under Tc17 
conditions with indicated treatment, rested overnight and restimulated with 100 U/ml IL-2 for indicated 
times under indicated treatment. Numbers in histograms represent MFI. Bars show fold MFI changes 
relative to control. (B-E) CD8+ T cells were spin transduced twice with retroviruses expressing either 
constitutive active P-STAT5 (pMIG STAT5) or constitutive active P-STAT3 (pMIG STAT3) or GFP alone 
(pMIG empty) as indicated. Then, CD8+ T cells were differentiated for 3 days under Tc17 conditions, 
rested for 3 days and re-cultured under Tc17 conditions for further 3 days. (B) Flow cytometric analysis 
of P-STAT5 (Y694) in CD8+ T cells. Dot plots show three subsets, based on the GFP expression intensity 
(GFP-negative, neg, GFP-intermediate, int, and GFP-high, high) for further analysis of P-STAT5 (Y694) 
expression in each subset. Numbers in histograms represent MFI. (C) Flow cytometric analysis of IL-17A+ 
GFP+ CD8+ T cells. Contour plot to the left shows four subsets, based on the GFP expression intensity 
(GFP-negative, neg, GFP-low, lo, GFP-intermediate, int, and GFP-high, hi) for analysis of percentages of 
IL-17A+ CD8+ T cells in each subset (graph shown to the right). (D) Flow cytometric analysis of GFPhigh IL-
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17A+ CD8+ T cells. Bars show percentages of GFPhigh IL-17A+ CD8+ T cells (E) Flow cytometric analysis of IL-
17A+ GFP+ CD8+ T cells after transduction with retroviruses expressing either constitutive active P-STAT3 
(pMIG STAT3) or GFP alone (pMIG empty). Bars to the left show fold IL-17A inhibition by DMF in GFPneg 
Tc17 cells. Bars to the right show fold IL-17 inhibition by DMF in GFPhigh Tc17 cells. (F) Flow cytometric 
analysis of IL-17A+ CD8+ T cells differentiated for 3 days under Tc17 conditions with indicated treatment 
(35 µM STAT5i). Contour-plots and histograms are representative for three (A, B, D) independent 
experiments. Bars show mean ± SD from (A, C) three, (F) four or (E) five combined experiments. 
Statistical analysis was performed using unpaired two-tailed Student’s t-test (ns P>0.05, *P<0.05, 
**P<0.01, *** P<0.001). 
 
 
5.8.2 DMF/ROS axis suppresses IL-17 production of Tc17 cells by 
elevated AKT/FOXO1/T-bet pathway  
As the inhibition of STAT5 could only partially restore the IL-17 production in Tc17 cells, we 
analysed further IL-2 downstream signalling pathways. The CTL fate of CD8+ T cells is 
determined by PI3K-AKT signalling (Macintyre et al., 2014), which is activated by IL-2 (Liao, Lin, 
& Leonard, 2013). Since we could show that DMF induced a shift towards a CTL-like signature 
in Tc17 cells on the one side and increased IL-2 signalling on the other, we thought to analyse 
the impact of DMF on the PI3K-AKT pathways. 
DMF increased the phosphorylation of AKT at the mTORC2-dependent S473 as well as on the 
PDK1-dependent site T308 in a ROS-dependent manner in Tc17 cells (Fig. 11 A, B). The lipid 
phosphatase PTEN limits activation of AKT and mTORC2 by their dephosphorylation, thereby 
counteracting the activity of PI3K (Ardestani, Lupse, Kido, Leibowitz, & Maedler, 2018). It has 
been shown that upregulated ROS can inhibit phosphatases by oxidation of their catalytic 
residues (Kamata et al., 2005). Accordingly, we found hampered Pten expression in DMF-
treated Tc17 cells (Fig. 11 C), suggesting that reduced PTEN levels contributes to the increased 
phosphorylation of AKT. AKT-mediated phosphorylation of the transcription factor FOXO1 
leads to the termination of its transcriptional activity (Finlay & Cantrell, 2011). In line, DMF-
treated Tc17 cells showed increased phosphorylation of FOXO1/3a (Fig. 11 D) and 
upregulation of T-bet (Fig. 8 D), a transcription factor suppressed by FOXO1 (Michelini, 
Doedens, Goldrath, & Hedrick, 2013; Rao, Li, Bupp, & Shrikant, 2012). To analyse the 
contribution of AKT/FOXO1/T-bet pathway to the DMF-mediated IL-17 suppression, we 
differentiated WT and T-bet-deficient (Tbx21-/-) CD8+ T cells under Tc17 cell conditions and 
treated them with DMF and a specific AKT1/2 inhibitor (AKTi). The use of AKTi increased the IL-
17 production in control- and to a significantly higher extent in DMF-treated WT, but not in 
Tbx21-/- Tc17 cells (Fig. 11 E), thus indicating that T-bet is required for the IL-17 suppression by 
enhanced AKT signalling. In addition, the DMF-mediated IL-17 inhibition was less pronounced 
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in Tbx21-/- as compared to WT Tc17 cells (Fig. 11 F), demonstrating a contribution of the 
AKT/FOXO1/T-bet pathway to the DMF-mediated IL-17 limitation in Tc17 cells, in addition to 
enhanced STAT5 signalling (Fig. 11 G). 
 
 
Figure 14: ROS suppress IL-17 production in Tc17 cells via increased AKT/FOXO1/T-bet signalling 
  
63 Results 
(A, B) Flow cytometric analysis of (A) P-AKT(S473) and (B) P-AKT(T308) in CD8+ T cells differentiated for 2 
days under Tc17 conditions with indicated treatment, rested overnight and restimulated with 100 U/ml 
IL-2 for 2 h under indicated treatment. Numbers in histograms represent MFI. Bars show fold MFI 
change relative to control. (C) Fold change of normalized expression counts of Pten from the dataset 
described in Figure 4 as determined by RNA-Seq and relative to DMF-treated Tc17 cells. (D) Flow 
cytometric determination of P- FOXO1(T24)/FOXO3a (T32) in CD8+ T cells differentiated for 2 days under 
Tc17 conditions with indicated treatment. Numbers in histograms represent MFI. Bars show fold MFI 
change relative to control. (E) Flow cytometric analysis of IL-17A+ and IFN-+  WT and Tbx21-/- CD8+ T 
cells differentiated for 3 days under Tc17 conditions with indicated treatment. Numbers in plots 
represent % of gated cells. (F) Flow cytometric analysis of IL-17A+ CD8+ WT and Tbx21-/- CD8+ T cells 
differentiated for 3 days under Tc17 conditions with indicated treatment. Bars show fold IL-17A 
inhibition by DMF. (G) Schematic DMF/ROS influence on IL-2 signalling, leading to IL-17 suppression in 
Tc17 cells. Modified from (Ardestani et al., 2018; Haddadi et al., 2018). Histograms and contour plots are 
representative for three (A, B), four (E) or five (D) independent experiments. Bars show mean ± SD from 
three (A-C), four (E, F) or five (D) combined experiments. (A-F) Statistical analysis was performed using 
unpaired two-tailed Student’s t-test (ns p>0.05, *p<0.05, **p<0.01, ***p<0.001). 
 
 
5.9 IL-17 production is differentially regulated in Tc17 and Th17 cells 
Besides FOXO1 and T-bet, the PI3K/AKT pathway also induces mTORC1 (Ardestani et al., 2018; 
Finlay & Cantrell, 2011). In line with the elevated PI3K/AKT pathway, we found an upregulation 
of mTOR-associated genes after DMF treatment of Tc17 cells (Fig. 12 A). In particular, 
phosphorylation of its downstream target S6 was elevated after DMF treatment (Fig. 12 B), 
demonstrating increased activity of mTORC1. In Th17 cells, mTORC1 is a positive regulator of 
IL-17 production, as the rapamycin-mediated mTORC1 inhibition limits IL-17 (Shi 2011). 
However, in contrast to Th17 cells, rapamycin did not limit IL-17 production in Tc17 cells (Fig. 
12 C, D). Furthermore, the inhibition of AKT failed to influence the production of IL-17 in Th17 
cells (Fig. 12 E), whereas it was induced in Tc17 cells (Fig. 11 E).  
Hence, these data indicate that AKT and mTORC1 signalling differentially impact the  
IL-17 production of Th17 and Tc17 cells (Fig. 11 G and Fig. 12 F). 
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Figure 15: Differential impact of AKT- and mTORC1-signalling on IL-17 production of Tc17 and Th17 
cells 
(A) Heatmap shows color-coded z-scores for the rlog transformed batch-corrected expression values 
from the dataset described in Figure 4. Displayed are the 16 most differentially upregulated mTOR 
signalling-associated genes according to KEGG database in Tc17 cells treated with DMF compared to 
control. (B) Flow cytometric analysis of P-S6(S235/236) in CD8+ T cells differentiated for 3 days under 
Tc17 conditions with indicated treatment. Bars show fold MFI change of P-S6 relative to control. (C, D, E) 
Flow cytometric analysis of IL-17+ CD4+ or CD8+ T cells differentiated for 3 days under type 17 conditions 
with indicated treatment. (F) Schematic influence of IL-2 signalling on Th17 cells. Modified from 
(Ardestani et al., 2018; Haddadi et al., 2018). Histogram in D is representative for three independent 
experiments. Bars show mean ± SD from (B, C, E) three or (D) four combined experiments. Statistical 
analysis was performed using unpaired two-tailed Student’s t-test (ns P>0.05, *P<0.05, **P<0.01, 
***P<0.001). 
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5.10 DMF suppresses IL-17 production of human Tc17 cells in a ROS-
dependent manner 
IL-17-producing CD8+ T cells have been found in acute active and chronic lesions of MS patients 
(Tzartos et al., 2008) and Tc17 cells support the pathogenicity of Th17 cells by IL-17 production 
during the onset of EAE (Huber et al., 2013).  
Our data acquired in the murine system demonstrated that DMF via GSH-depletion and ROS 
induction is able to suppress the Tc17 cell fate, including the production of pro-inflammatory 
IL-17. To examine whether the findings obtained in mouse Tc17 cells can be translated to the 
human system, we differentiated human Tc17 cells in vitro. These experiments were done in 
collaboration with Dr. C. Zielinski from Technical University of Munich.  
 
 
Figure 16: DMF treatment limits IL-17 production in human Tc17 cells 
(A-C) CD8+CD45RA- T cells were sorted from human peripheral blood of healthy donors and 
differentiated under Tc17 conditions for 4 days with indicated treatment. (A, C) Flow cytometric analysis 
of IL-17A+ or IFN-+ CD8+ T cells. Numbers in plots represent % of gated cells. Data are representative of 
three individual experiments and donors. (B) ELISA analysis of IL-17 in the supernatant from cultures 
described in A. Bars give mean ± SD from two combined experiments with different donors. Statistical 
analysis was performed using unpaired two-tailed Student’s t-test (ns P>0.05, *P<0.05, **P<0.01, 
***P<0.001). 
 
Briefly, CD8+ CD45RA- T cells of healthy donors were sorted, cultured under Tc17 conditions 
and treated with control, DMF alone or in combination with GSH as indicated. After four days, 
IL-17 and IFN- levels were analysed by flow cytometry and the measurement of IL-17 
concentration in cell culture supernatant was additionally determined by ELISA.  
In accordance with the findings in the murine system, DMF significantly suppressed the IL-17 
production also in human Tc17 cells in a ROS-dependent manner (Fig. 13 A, B). Surprisingly,  
IFN- levels were not influenced by DMF treatment (Fig. 13 C). 
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Taken together, DMF-mediated ROS upregulation suppresses IL-17 production in murine and 
human cells in comparable manner, whereas production of IFN- seems to be differentially 
regulated. 
 
5.11 DMF treatment reduces frequencies of IL-17-producing CD8+ T cells 
in MS patients 
CD8+ T cells contribute to autoimmune processes in the CNS by production of pro-
inflammatory IL-17 (Huber et al., 2013). Our aforementioned data revealed that the RRMS 
drug DMF suppresses IL-17 production by murine as well as human CD8+ T cells in vitro. 
Furthermore, oral DMF application limited T cell infiltration in the CNS and diminished clinical 
disease symptoms in the mouse model. To examine the impact of DMF treatment on CD8+ and 
CD4+ T cells in RRMS patients, we analysed the frequencies of IL-17-and IFN--producing 
memory CD8+ and CD4+ T cells before and after the first year of treatment. Biosampling and 
analysis were performed in collaboration with Dr. B. Tackenberg from the University Hospital 
Marburg. 
  
 
Figure 17: DMF treatment limits IL-17 production of CD8+ T cells in MS patients 
(A) Flow cytometric analysis of percentages of IL-17A+ or IFN-+ CD8+ CD14- CD45RA- T cells and (B) 
percentages of IL-17A+ or IFN-+ CD4+ CD14- CD45RA- T cells from PB of treatment naïve RRMS patients  
(n = 18) before (0 M) and after 12 months (12 M) of Tecfidera therapy. Statistical analysis was 
performed using paired two-tailed Student’s t-test. 
 
 
We analysed PB from 18 naïve DMF responders, who were stable in terms of relapses, 
new/enlarging T2 lesions in magnetic resonance imaging (MRI) and the expanded disability 
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status scale (EDSS) after the first year of Tecfidera treatment and compared cytokine 
production with cytokine levels of naïve patients before treatment. 
In accordance with the previous data, the frequencies of IL-17-producing memory 
CD8+CD45RA- T cells were significantly reduced, demonstrating a positive response to Tecfidera 
treatment. In contrast to the in vitro data, also the IFN- production of memory CD8+ T cells 
was reduced (Fig. 14 A). In addition, we analysed the influence of DMF on memory CD4+ T cells 
and found also here a significant reduction of IFN- producers, whereas the frequencies of IL-
17-producing memory CD4+ T cells were not affected, again demonstrating the preferential 
influence of DMF on IL-17-producing CD8+ T cells (Fig. 14 B). 
Thus, we could show that DMF treatment limits IL-17 production in CD8+ T cells also in RRMS 
patients. In addition to the in vitro data, also the IFN- production of CD8+ and CD4+ T cells was 
diminished, assuming a contribution of further indirect effects in vivo. 
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6. Discussion 
 
Immune modulatory impact of DMF 
DMF (marketed as Tecfidera®) is approved for treatment of RRMS since early 2013, but its 
mode of action has not been fully elucidated (Bomprezzi, 2015). What has become clear so far 
is that DMF does not only have a single mechanism by which it shows its effect, but rather it 
exerts a multitude of effects on the immune system. These effects vary from reduced 
infiltration of immune cells to the CNS (H. Chen et al., 2014), histone hypermethylation of 
tumour cells (Sullivan et al., 2013), elevated ROS levels by depletion of GSH (Diebold et al., 
2017; Ghoreschi et al., 2011) to an induction of antioxidant responses via the NRF2 pathway in 
neurons and glial cells (Linker & Haghikia, 2016). However, a direct influence of DMF on IL-17-
producing CD8+ T cells that contribute to the pathogenicity of MS has not been evaluated so 
far. This thesis provides new insights in DMF’s mode of action by revealing its inhibitory impact 
on murine and human Tc17 cells via ROS accumulation.  
 
6.1 ROS modifies Tc17 cell fate 
6.1.1 DMF suppresses IL-17 in Tc17 cells via early GSH-depletion and 
subsequent ROS accumulation  
In several studies it has been shown that DMF binds to intracellular GSH and decreases its 
antioxidative capacity, thereby leading to elevated ROS levels in various cell types (Ghoreschi 
et al., 2011; Hoetzenecker et al., 2012; Sullivan et al., 2013; Zheng et al., 2015). Depending on 
their concentration, on the one hand ROS are able to support CD8+ T cell activation (Sena et 
al., 2013), on the other they can also result in a tremendous impairment of T cell function (Mak 
et al., 2017). Although a reduction of CD8+ T cells was uncovered upon DMF treatment, the 
functional impact of DMF on CD8+ T cells, in particular IL-17-producing CD8+ T cells, remained 
elusive. 
Here, we demonstrated that DMF treatment of Tc17 cells in vitro resulted in a 
significant reduction of intracellular GSH levels, followed by ROS upregulation at early time 
points of differentiation. After 24 h of differentiation a reversed picture with a significant 
reduction of ROS and an increase of NRF2 target genes emerged, pointing to the induction of 
antioxidant pathways, already described for DCs, neurons and astrocytes (Ghoreschi et al., 
2011; Linker & Haghikia, 2016; Scannevin et al., 2012). Surprisingly, the early accumulation of 
ROS was sufficient to suppress IL-17 and upregulate IFN- production in Tc17 cells, as the 
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addition of reduced GSH was able to restore cytokine production to a large extend. To 
evaluate the susceptibility of established Tc17 cells to DMF, we added DMF at later time 
points. Of note, after at least 17 h upon begin of culture, DMF was not able to limit IL-17 
anymore, demonstrating the importance of early DMF presence in order to inhibit IL-17 
production of Tc17 cells.  
Although we detected elevated ROS levels in Th17 cells as well, we did not observe a 
significant IL-17 suppression. This is in contrast to previously published data describing a ROS-
mediated inhibitory effect on IL-17 production in Th17 cells, the mechanism however remains 
obscure (Gerriets & Kishton, 2014). These contrary results may be due to differences in the 
experimental setup of our and their study. Whereas we used DMF to induce ROS upregulation 
in our experiments, Gerriets at el. made applied dichloroacetate (DCA), an inhibitor of the 
pyruvate dehydrogenase kinase (PDHK). DCA treatment suppressed glycolysis and increased 
oxidative metabolism including ROS levels in Th17 cells. Apart from differential ROS induction 
among the studies, also the levels differed as well. Additionally, while in our experimental 
setup, DMF only induced moderate ROS increase at early time points, Gerriets at al. showed 
high ROS accumulation even after three days of differentiation, indicating a more prominent 
and prolonged ROS upregulation. Taken together, while DMF leads to moderate ROS 
accumulation early in the differentiation process, DCA induced higher ROS concentrations, 
probably over a longer time period, which might explain the differential influence on IL-17 
production in Th17 cells. Hence, future work must be carried out to assess the impact of 
differentially created ROS in T cells. Furthermore, it should be examined at which 
concentrations ROS might have suppressive effects on Th17 cells to ensure safe and effective 
therapies. 
Finally, we demonstrated the stability of IL-17 suppression in Tc17 cells by DMF. 
Interestingly, IL-17 levels were diminished to a similar extend in cells treated for six days 
continuously with DMF and cells treated for three days, followed by a three-day resting period 
without DMF. This indicated a persistent impact of DMF on Tc17 cells with relevance for 
therapy. 
Thus, it can be concluded that the DMF-mediated GSH depletion leads to an early moderate 
ROS upregulation, causing long-lasting suppressive effects on IL-17 production of Tc17, but not 
Th17 cells. DMF preferentially inhibits IL-17 production of Tc17 cells when administered at 
early stages of differentiation. This observation is supported by a study showing that early 
DMF therapy is highly effective especially in newly-diagnosed cases of MS (Gold  G.; Phillips, J. 
T.; Fox, R. J.; Zhang, A.; Meltzer, L.; Kurukulasuriya, N. C., 2015). Furthermore, continuous 
  
70 Discussion 
application of DMF might be required in therapy for RRMS patients in order to suppress newly 
developing pathogenic Tc17 cells. 
 
6.1.2 Involvement of DMF/ROS axis on T cell proliferation and apoptosis 
Besides the intensity of TCR signalling, co-stimulation and cytokines, the activation of T cells is 
influenced by ROS (Franchina et al., 2018). ROS are generated in the mitochondrial electron 
transport chain (ETC) and their levels are physiologically balanced by antioxidants like GSH 
(Franchina et al., 2018). Depending on concentration and exposure time, ROS can influence T 
cell responses in a positive or negative manner (Mak et al., 2017; Sena et al., 2013). 
To evaluate whether DMF via ROS accumulation suppressed proliferation of Tc17 cells and 
thus influenced their cytokine production, we performed CFSE staining and detected only a 
tendency of reduced proliferative capacity in DMF-treated cells. By comparing the IL-17 
suppression in each proliferation cycle, it became clear that DMF limits IL-17 independently of 
proliferation, as the frequencies of IL-17-producing cells were reduced to a similar extent in 
each proliferation cycle. Thus, the increased ROS levels induced by DMF do not impair 
proliferation of Tc17 cells and thereby cytokine production. 
The occurrence of lymphopenia or PML in some MS patients under Tecfidera treatment threw 
a shadow onto the overall positive safety profile of DMF (Linker & Haghikia, 2016). To 
elucidate if the IL-17 inhibition was a side effect of apoptosis induced by DMF, we performed 
Annexin V and propidium iodide staining on DMF-treated Tc17 cells compared to controls. It 
became obvious that DMF at immune modulatory concentrations hardly induced apoptosis in 
Tc17 cells, whereas higher DMF concentrations were pro-apoptotic, in accordance with 
previous reports (Diebold et al., 2017). Interestingly, the neutralisation of ROS by GSH reversed 
the cell death induced by DMF, demonstrating a dose-dependent impact of ROS levels: At 
moderate levels, ROS exerted immune modulatory effects, whereas high ROS levels had 
detrimental impact by inducing cell death.  
Taken together, DMF executes the Tc17 suppression neither via elevated apoptosis nor 
reduced proliferation but probably by interfering with further signalling pathways. 
 
6.1.3 ROS shifts the Tc17 profile towards a CTL-like signature 
After having demonstrated the influence of elevated ROS levels for limiting IL-17 production in 
Tc17 cells, we sought to elucidate whether DMF-induced ROS have broader implications on the 
transcriptome of Tc17 cells. Hence, we performed RNA-Seq to compare gene expression 
profiles of Tc17 cells treated with control, DMF alone or in combination with GSH. Gene 
expression profiles clearly showed the global influence of DMF treatment and the reversion by 
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GSH co-treatment on Tc17 cells. PCA analysis highlighted the impact of the DMF-mediated ROS 
increase on Tc17 cell transcriptome by pointing out the similar profiles of control and GSH co-
treated cells. Functional analysis via GSEA revealed a significant reduction of Tc17-associated 
genes in DMF-treated samples whereas CTL-associated genes were significantly enriched, 
including those involved in the induction of cytotoxic molecules as perforin and granzymes. As 
addition of GSH could reverse these changes, we could clearly show that DMF via ROS 
accumulation was responsible for the reprogramming towards a CTL-like phenotype. 
Furthermore, the type 17 TF RORt was reduced on protein level, whereas T-bet, crucial for 
effector CTL differentiation, was upregulated in DMF-treated samples (Kallies & Good-
Jacobson, 2017), suggesting that ROS can act as modulator of T cell plasticity.  
Collectively, these data indicate that DMF-induced ROS downregulates Tc17 cells, whereas 
boosts CTL signatures, indicating their ability to influence CD8+ T cell plasticity. Since Tc17 cells 
contribute to several pathologies including MS, psoriasis and type 1 diabetes (Srenathan et al., 
2016), actively regulating ROS levels might represent a potential therapeutic tool for these 
immunopathologies. 
 
6.1.4 DMF alters histone modifications of Tc17 cells in a ROS-dependent 
manner 
Oxidative stress can exert a strong influence on immunopathologies, including cancer, diabetes 
and neurodegenerative diseases. There is growing evidence that ROS influences chromatin 
structure, DNA methylation and histone modifications. The resulting cellular changes including 
altered gene expression are disease-driving mechanisms of the aforementioned pathologies 
(Kreuz & Fischle, 2016). Histones especially are extensively affected by ROS, which leads to an 
altered structure that influences post-translational modifications (Kreuz & Fischle, 2016). 
Furthermore, it was proved that permissive histone modifications such as H3K27Ac and 
H3K4me3 are essential for gene expression of the Il17 locus (Akimzhanov, Yang, & Dong, 
2007).   
To assess whether ROS influences histone modifications in Tc17 cells, we performed ChIP 
assays at the promoter and an enhancer of the Il17 locus in Tc17 cells treated with control, 
DMF alone or in combination with GSH. We could demonstrate that the DMF-promoted ROS 
specifically suppressed permissive histone modifications including H4Ac, H3K27Ac and 
H3K4me3 in Tc17 cells, whereas the repressive methylation H3K27me3 was not influenced. 
This was quite surprising, as high fumarate concentrations have been shown to inhibit α-
ketoglutarate-dependent dioxygenases that are involved in DNA and histone demethylation 
(Laukka et al., 2016; Xiao et al., 2012). In order to address the question whether DMF also 
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influences DNA and/or histone methylation genome-wide, which has been reported in 
previous studies (Xiao et al., 2012), ATAC-Seq or ChIP-Seq analysis would be required.  
Besides its direct influence on histones, ROS have been implicated in the induction of HDAC 
activity, enzymes that catalyse deacetylation and thus gene silencing (Kreuz & Fischle, 2016). 
Additionally, it was shown previously that ROS can suppress expression of members of cell 
junction protein as E-cadherin by an HDAC1-dependent decrease of H3Ac, H4Ac as well as 
H3K4me2 in human hepatoma cells (Lim et al., 2008). Of note, it was shown by Yang et al that 
IL-2 induced STAT5 is able to reduce permissive histone modifications such as H3Ac at the Il17 
locus by recruitment of a histone deacetylator adaptor protein (X. P. Yang et al., 2011). 
To investigate the contribution of HDACs to the ROS-mediated IL-17 suppression, we co-
treated Tc17 cells with DMF and the HDAC inhibitor TSA. Our data indicate that the reduction 
of permissive histone acetylation was in parts mediated by increasing HDAC recruitment or 
function, as HDAC inhibition by TSA partially restored IL-17 levels.  
In summary, DMF-mediated ROS increase can influence histone modifications, leading to 
reduced permissive acetylation and methylation at the Il17 locus. This was at least partially 
mediated by enhancement of HDAC function or recruitment. 
 
6.2 ROS alter Tc17 network by enhancing IL-2 signalling  
Our data showed the key role of ROS in Tc17 cell suppression, as neutralisation by GSH or 
Trolox reversed the effects. In Tc17 cells, besides ROS IL-2 was also absolutely required for the 
limitation of IL-17 production by DMF. Furthermore, the functional analysis of RNA-Seq data by 
GSEA revealed an enrichment of IL-2/STAT5-associated genes in DMF-treated Tc17 cells as 
compared to control. These results show that IL-2 is not only necessary for IL-17 inhibition but 
is also elevated by DMF/ROS axis, suggesting interdependency between ROS and IL-2 signalling 
during DMF treatment. However, GSH depletion as well as ROS induction upon DMF addition 
were not dependent on the presence of IL-2. Therefore, we hypothesised that ROS by 
enhancing IL-2 signalling caused the suppression of IL-17 in Tc17 cells. 
IL-2 has been shown to promote naïve CD4+ T cell differentiation into Th1 and Th2 cells, 
whereas Th17 cell differentiation is suppressed (Liao et al., 2013). Besides its actions on CD4+ T 
cells, IL-2 supports the development of naïve CD8+ T cells into effector and memory CTL with 
induction of IFN-, perforin and granzymes (Pipkin et al., 2010). Our data demonstrated a ROS-
dependent shift from Tc17 signature towards a CTL-like profile by DMF, resulting in prevention 
of CNS autoimmunity. It is conceivable that these mechanisms also count for CTLs, in which 
ROS by enhanced IL2 signalling would drive terminal effector differentiation (Pipkin et al., 
2010). The fact that accelerated IL-2 can induce apoptosis in CTLs (Shrikant & Mescher, 2002), 
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makes this cytokine promising for tumour therapy. In this context, ROS via IL-2 would induce 
apoptosis in tumour-infiltrating CTLs and thus contribute to tumour progression. 
With keeping the importance of IL-2 signalling for DMF-mediated IL-17 suppression in mind, 
we sought to analyse IL-2 downstream pathways in order to elucidate mechanisms of Tc17 fate 
suppression more in detail. 
 
6.2.1 Elevated ROS increase STAT5 and PI3K/AKT signalling, thereby 
limiting IL-17 inhibition 
Our results demonstrate that DMF via ROS accumulation enhances IL-2 signalling and elevated 
phosphorylation of STAT5 in Tc17 cells. In accordance to the published data for Th17 cells (Liao 
et al., 2013; X. P. Yang et al., 2011), STAT5 can limit IL-17 production also in their CD8+ 
counterparts. It was shown that STAT3 and STAT5 compete for common binding sites at the 
Il17 locus and thereby regulate gene transcription by direct opposing actions in Th17 cells (X. 
P. Yang et al., 2011). By performing STAT3 overexpression we could confirm a comparable 
mechanism for Tc17 cells, as high STAT3 levels diminished the IL-17 suppression partially. The 
co-treatment of cells with DMF and a pharmacological STAT5 inhibitor revealed a contributing 
effect of STAT5 to the DMF/ROS-mediated IL-17 suppression. 
Besides STAT5, IL-2 induces also PI3K/AKT pathways and thereby determines CTL fate 
(Macintyre et al., 2014). This is in line with our finding that DMF via ROS suppress Tc17 cells 
and equips them with a CTL-like signature, including the transcription factor T-bet. 
Furthermore, our data demonstrate an ROS-mediated elevated activation of AKT, probably 
caused by a diminished expression of the phosphatase Pten. This is in accordance with 
previous data, which reported an inhibitory effect of ROS on the activity of phosphatases by 
oxidation of their catalytic residues (Kamata et al., 2005) and was already described for PTEN 
in RAW macrophages (Leslie et al., 2003) and the protein-tyrosine phosphatase PTPN2 in 
hepatocytes (Gurzov et al., 2014). Elevated AKT activity results in the increased 
phosphorylation of FOXO1, leading to the termination of its transcriptional activity (Finlay & 
Cantrell, 2011). Accordingly, DMF-treated Tc17 cells showed enhanced P-FOXO1/3a levels and 
upregulation of T-bet, a TF suppressed by FOXO1 (Michelini et al., 2013; Rao et al., 2012). As 
DMF could inhibit IL-17 in T-bet-deficient Tc17 cells to a lesser extent, we assumed a T-bet 
requirement for suppression of IL-17. Furthermore, we demonstrated that the partial IL-17 
limitation by AKT signalling was mediated via T-bet, as inhibition of AKT in T-bet-deficient cells 
had no influence on IL-17 production. Our data is in line with previous literature, showing that 
T-bet hinders Tc17 cell differentiation (Intlekofer et al., 2008; Xin et al., 2016). In addition, 
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further work has to be performed to reveal the contribution of further IL-2 downstream 
pathways, as ERK signalling, to IL-17 suppression by DMF. 
In summary, DMF alters Tc17 transcriptional program at least partially via enhanced STAT5 as 
well as PI3K/AKT/FOXO1/T-bet signalling in a ROS-dependent manner. 
 
6.2.2 Model of differential IL-17 regulation in Th17 and Tc17 cells 
We show that DMF treatment preferentially suppresses the IL-17 production of Tc17 cells, 
whereas Th17 cell remain largely unaffected. This might be due to a different sensitivity 
towards ROS levels in CD4+ and CD8+ T cells, as discussed in 6.1.1. 
A further possibility for the selective IL-17 suppression in Tc17 cells by DMF might be the 
differential AKT- and mTORC1-signalling in Tc17 and Th17 cells. Whereas IL-2-induced AKT 
suppressed the IL-17 production by Tc17 cells, it failed to do so in Th17 cells, pointing to 
signaling differences between CD4+ and CD8+ T cells.  
Furthermore, our data revealed differences in mTORC1 signalling between Th17 and Tc17 cells. 
Besides FOXO1 and T-bet, also mTORC1 is induced by the PI3K/AKT pathway (Ardestani et al., 
2018; Finlay & Cantrell, 2011). In accordance with the elevated PI3K/AKT signalling, we 
detected an enhanced mTORC1 activity after DMF treatment in Tc17 cells, indicated by 
elevated levels of mTOR signalling-associated genes including P-S6. In Th17 cells, mTORC1 is 
supposed to be a positive regulator of IL-17, as rapamycin suppressed its production (L. Z. Shi 
et al., 2011). However, in contrast to Th17 cells, the mTORC1 inhibitor rapamycin could not 
limit IL-17 in Tc17 cells, although suppression of P-S6 revealed its effectiveness.  
A possible explanation for this contrast could be given by differential signalling, as already 
reported for IL-2 signalling in CD4+ versus CD8+ T cells: whereas CD4+ T cells show a biphasic 
STAT5 phosphorylation, only one P-STAT5 peak is detectable upon IL-2 stimulation in CD8+ T 
cells (G. A. Smith et al., 2017). Therefore, additional functional differences in IL-2 downstream-
signalling cascades in both T cell classes are conceivable. However, further work has to be 
carried out to investigate the exact differences between Tc17 and Th17 cells concerning their 
responsiveness to DMF treatment. 
Taken together, the preferential IL-17 suppression in Tc17 cells as compared to Th17 cells 
could be explained by several convergent effects. Besides a different ROS sensitivity in CD4+ 
and CD8+ T cells, also variances in mTORC1 and AKT signalling might contribute to a differential 
response to DMF treatment. 
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6.3 Impact of DMF treatment on EAE pathogenesis 
6.3.1 The course of EAE is attenuated by oral DMF application  
Multiple sclerosis is a heterogenous, T cell-mediated disease characterized by demyelination 
and multifocal inflammation. Besides T cells, inflammatory lesions are additionally infiltrated 
by B cells, monocytes, macrophages and plasma cells, indicating a multicellular 
pathophysiological process leading to axonal damage (Comabella & Khoury, 2012; Dendrou et 
al., 2015; Nylander & Hafler, 2012). Several in vivo and in vitro studies point to the beneficial 
impact of DMF treatment during MS and the animal model EAE (Ghoreschi et al., 2011; Gold  
G.; Phillips, J. T.; Fox, R. J.; Zhang, A.; Meltzer, L.; Kurukulasuriya, N. C., 2015). It has been 
reported that DMF attenuates the progression of disease by various mechanism, including 
limitation of immune cell infiltration into the CNS via HCA2 receptor (H. Chen et al., 2014), 
modulation of DCs and B cells towards an anti-inflammatory phenotype (Ghoreschi et al., 
2011; Li et al., 2017) and induction of anti-oxidative response in neurons and glial cells (Linker 
& Haghikia, 2016). Additionally, our aforementioned data show that DMF treatment directly 
impacts the in vitro differentiation of Tc17 cells that contribute to autoimmune processes in 
the CNS (Huber et al., 2013).  
Here we show that oral administration of DMF can limit severity of clinical symptoms during 
EAE as well as reduce the infiltration of IL-17-producing CD8+ T cells into dLN and CNS as 
compared to control group. This demonstrates that oral DMF application is able to attenuate 
EAE severity, as already described in the literature (Ghoreschi et al., 2011; Linker et al., 2011; 
Schulze-Topphoff et al., 2016). 
Taken together, the improved disease outcome after oral DMF treatment is probably the result 
of a multitude of mechanisms, whereby the effect on IL-17-producing CD8+ T cells represents 
one. Therefore, besides its suppressive effect on Tc17 cell differentiation in vitro, oral DMF 
treatment can limit Tc17 cells also in vivo, demonstrated by reduced percentages of IL-17-
producing CD8+ T cells in dLN and CNS compared to the control. However, based on this data it 
is not possible to distinguish between direct and indirect DMF effects on Tc17 cells.  
 
6.3.2 DMF treatment limits co-pathogenic function of Tc17 cells in EAE 
A series of studies have highlighted the pathogenic role of IL-17 in the development of MS by 
using EAE (Langrish et al., 2005). IL-17 augments inflammatory processes in the CNS by 
promoting the generation of further pro-inflammatory cytokines and chemokines, which 
attract neutrophils and macrophages to inflammation sites (Jin & Dong, 2013). In addition,  
IL-17 production has been associated with active disease and was detected in brain lesions of 
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MS patients (Fletcher, Lalor, Sweeney, Tubridy, & Mills, 2010). Although, MS has been 
considered as being driven by CD4+ T cells, recent studies revealed the contribution of other 
immune cells, including CD8+ T cells (Friese & Fugger, 2009; Salou, Nicol, Garcia, & Laplaud, 
2015). The fact that CD8+ T cells outnumber CD4+ T cells 3- to 10-fold in chronically inflamed 
MS plaques gives further evidence for an important role of CD8+ T cells in MS (Babbe et al., 
2000; Booss et al., 1983). Furthermore, previous data from our group revealed a co-pathogenic 
function of Tc17 cells during the onset of EAE by enhancing the pathogenicity of Th17 cells via 
their IL-17 production (Huber et al., 2013).  
After having demonstrated the beneficial impact of orally administered DMF in EAE on the one 
hand and the stable IL-17 suppression by Tc17 cells in vitro on the other, we sought to 
elucidate a direct functional effect by DMF on Tc17 cells in vivo. This is why we chose an 
adoptive transfer EAE model to assess the impact of DMF treatment on Tc17 cells resulting in 
low IL-17 production in vivo.  
In this model, Tc17 cells were differentiated in vitro, treated with control or DMF and 
adoptively transferred into recipient Irf4-/- mice that are resistant to EAE (Brüstle et al., 2007; 
Huber et al., 2013). Simultaneously, MOG-specific TCR-transgenic CD4+ 2D2 T cells we 
transferred into the mice to induce EAE. Of note, transferred DMF-treated Tc17 cells evoked 
significantly less severe EAE symptoms characterised by significantly diminished T cell 
infiltration in the CNS and elevated T cell numbers in dLNs, demonstrating that DMF treatment 
reduced pathogenicity of Tc17 cells. More importantly, the high IL-17 production of control-
treated Tc17 cells in dLNs correlated with a significant higher IL-17 production by Th17 cells in 
the CNS as compared to the animals that received DMF-treated Tc17 cells.  
In summary, these data reveal that DMF treatment limits the co-pathogenic function of Tc17 
cells by suppressing their IL-17 production. The reduced IL-17 levels of Tc17 cells are 
accompanied by a diminished pathogenic IL-17 production in Th17 cells, resulting in lower 
migration of both, IL-17-producing CD4+ and CD8+ T cells into the CNS. Furthermore, these 
experiments demonstrate the complex interaction between T cell subsets and underline the 
key role of IL-17 production by CD8+ T cells in EAE.  
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Figure 18: DMF disturbs the cooperation between Tc17 and Th17 cells during the onset of EAE 
Schematical display of the cooperation between Tc17 and Th17 cells during the onset of EAE (above) 
and the disturbed cooperation while DMF treatment (below). By their IL-17A production, Tc17 cells 
provide reverse help to Th17 cells and thereby increase their pathogenicity, including high IL-17A 
production. In the presence of DMF however, the IL-17 production of Tc17 cells is suppressed, resulting 
in a diminished pathogenicity of Th17 cells. Modified from (Huber & Lohoff, 2015) 
 
6.4 DMF treatment suppresses human IL-17-producing CD8+ T cells 
In accordance with the data obtained from murine Tc17 cells, we showed that DMF also 
suppresses the IL-17 production of human Tc17 cells in vitro. Similar to the murine system, the 
DMF-mediated inhibition of human cells was ROS-dependent, suggesting similar mechanisms. 
In contrast, IFN- production was not elevated upon DMF treatment, indicating differences in 
IFN- regulation between murine and human Tc17 cells.  
Along with the results in vitro, we demonstrated that a stable response to DMF therapy in 
RRMS patients was associated with a significant reduction of IL-17-producing CD8+ T cells. In 
accordance, in vitro data from murine Th17 cells, IL-17-producing CD4+ T cells were hardly 
affected. Therefore, the extent of IL-17 production in CD8+ T cells of RRMS patients with DMF 
treatment could be a reliable marker for determination of therapy success.  In contrast to the 
murine system, the IFN- production of CD8+ T cells of patients was reduced by DMF 
treatment, indicating again differential regulation of IFN- production in human and murine 
Tc17 cells. 
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Hence, DMF treatment suppresses the IL-17 production of murine as well as human CD8+ T 
cells, whereas IFN- seems to be regulated differently. 
 
6.5 Potential implications of DMF/ROS-mediated Tc17 suppression 
In the course of this study, moderate ROS accumulation, promoted by the MS drug DMF has 
been identified as a suppressor of human and murine Tc17 cells. Besides their pathogenic 
function in autoimmune processes of the CNS, these cells contribute to protective immune 
responses against bacterial, viral and fungal infections (Hamada et al., 2009; Naik et al., 2015; 
Nanjappa et al., 2017; Yeh et al., 2010). Therefore, the limitation of IL-17-producing CD8+ T 
cells during DMF therapy might also result in disturbed clearance of pathogens and should be 
part of future work. 
Furthermore, the role of pro-inflammatory IL-17 in tumour immunity has been highly 
discussed and is controversial (Qian et al., 2017). However, the majority of studies reported an 
inflammation-associated support of cancer development (Murugaiyan & Saha, 2009; Qian et 
al., 2017). In our study we revealed that DMF leads to a shift from IL-17-producing Tc17 cells 
towards cells with CTL signature in a ROS-dependant manner. Several points support a positive 
contribution of CTLs to anti-tumour responses by their production of IFN- and cytolytic 
molecules (Maher & Davies, 2004). IFN-, which is induced by DMF/ROS axis, has been shown 
to have direct and indirect anti-tumour properties (Qin et al., 2003). Additionally, the 
expression of cytotoxic molecules as perforin and granzymes in DMF-treated Tc17 cells was 
evaluated on mRNA level. However, the acquirement of cytotoxic functionality has to be 
proved by cytotoxicity assays and in vivo experiments of LCMV infection or tumour models. 
Finally, Tc17 cells contribute to the pathogenesis of psoriasis as they are present in psoriatic 
skin lesions and correlate with severity of psoriatic arthritis (Srenathan et al., 2016). 
Considering that fumarate has been successfully applied for treatment of psoriasis since the 
1990s (Reich et al., 2009), it is conceivable that the described suppression of Tc17 phenotype 
by DMF also applies for psoriasis, suggesting a common DMF-ROS-driven protective 
mechanism in Tc17-associated immune pathologies. 
In summary, the ability of DMF to suppress Tc17 cells and IL-17 production could influence 
other immune responses, especially during infections and cancer therapy. As DMF mediates its 
major effects via ROS, understanding the impact of oxidative stress on CD8+ T cell fate 
decisions should be analysed more in detail. 
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6.6 Final discussion and outlook 
The results reported in this study demonstrate that DMF, an approved treatment for RRMS, 
limits the pro-inflammatory IL-17 production in human and murine Tc17 cells ROS-
dependently. In detail, cell-permeable DMF binds to the ROS scavenger GSH and causes an 
accumulation of ROS at early time points. This early ROS increase is sufficient to induce a shift 
towards a CTL-like signature while suppressing Tc17 fate, leading to their reduced co-
pathogenic function during EAE. Thus, ROS was identified as an essential regulator of T cell fate 
and plasticity in Tc17 cells. The modification of Tc17 cells is accompanied by altered histone 
modifications: DMF via ROS suppresses permissive methylation and acetylation at the Il17 
locus, partially by interfering with HDACs. However, future work must be carried out to 
evaluate how DMF impacts epigenetic modifications in detail. Furthermore, we could 
demonstrate that IL-2 is required for the IL-17 inhibition by DMF and that the IL-2 downstream 
pathways PI3K/AKT/FOXO1 as well as STAT5 are upregulated by ROS and partially contributed 
to the IL-17 inhibition. Remarkably, the PI3K/AKT/FOXO1 pathway restricts IL-17 production 
only in Tc17 but not in Th17 cells, providing an explanation for the preferential suppression of 
CD8+ T cells. Thus, further work has to be performed to analyse the exact differences in IL-17 
signalling between Tc17 and Th17 cells. Accordingly, DMF-treated RRMS patients show a 
reduction of IL-17-producing CD8+ memory T cells whereas IL-17 production in CD4+ T cells 
remains unaffected. Consequently, the analysis of IL-17 production of CD8+ T cells in MS 
patients under DMF treatment could represent a novel and reliable marker of therapeutical 
success. 
Collectively, we show that DMF via ROS suppresses Tc17 cells fate, including its co-pathogenic 
role during EAE and MS. Hence, ROS is a potential regulator of CD8+ T cell plasticity and the use 
of pro-and antioxidants might represent a promising tool in preventing Tc17-mediated 
pathologies like MS, psoriasis or IL-17-driven tumorigenesis including pancreatic or colorectal 
cancer. 
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Figure 19: Influence of DMF on Tc17 cells 
Schematical display of the signalling in Tc17 cells in the absence (above) or presence of DMF (below). 
Cytoplasmic GSH levels neutralise basal ROS contents that are produced in the electron transport chain 
(ETC). In the presence of DMF, GSH is depleted and results in elevated ROS levels. Accumulated ROS 
enhances the IL-2 pathway, leading to upregulation of P-AKT and P-STAT5 signalling. P-STAT5 probably 
directly reduced Il17 transcription, whereas P-AKT via P-FOXO1 and T-bet suppresses Il17 expression. 
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